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With the goal of highlighting the myriad of 
novel research carried out by the medical stu-
dents of the George Washington University 
(GW) School of Medicine and Health Sciences 
(SMHS), we proudly present the 2017 edition 
of Fusion. The journal is an entirely student-
run publication; everything from the abstracts 
to the cover artwork was provided by students. 
Our goal as this year’s co-presidents of 
the William H. Beaumont Medical Research 
Honor Society was to build upon the tremen-
dous success of last year’s journal. This year’s 
edition was met with a record number of 
submissions, running the gamut from basic 
science to clinical public health research. We 
believe that our growing journal reflects an 
increasing trend of SMHS student participa-
tion in research and an expanding institu-
tional emphasis on research here at GW.
We would like to offer special congratu-
lations to Sharjeel Chaudhr y, Brendan 
Campbell, and Lauren Jacobs, this year’s first, 
second, and third prize winners, respectively, 
of the William H. Beaumont Medical Honor 
Society Student Research Award. Your 
research stood out among a truly impressive 
body of work and merits the opportunity to 
present to GW faculty and students at the 
22nd Annual SMHS Research Day.
This year’s edition of Fusion would not 
have been possible without the support of 
numerous individuals. First, we express our 
heartfelt gratitude to Fusion’s faculty advisor, 
Robert H. Miller, Ph.D., senior associate dean 
of research and Vivian Gill Distinguished 
Research Professor. We would also like to 
thank Sara VanDommelen, research admin-
istrator, for her invaluable logistical support. 
We thank Douglas Nixon, M.D., Ph.D., pro-
fessor and chair of microbiology, immunology, 
and tropical medicine and Walter G. Ross 
Professor of Basic Science Research at SMHS, 
for contributing this year’s faculty letter. We 
thank the SMHS Office of Communications 
and Marketing for the design and production 
of Fusion. Last but not least, we offer a special 
thank you to our fellow classmates — those 
who volunteered their time to our Editorial 
Board,as well as our authors, without whom 
this journal would not exist.
We hope you will enjoy and learn as much 
as we did from reading this year’s journal.
MICHAEL FROEHLICH, MSII
JACOB RUBIN, MSII
co-presidents of the William H. Beaumont 
Medical Research Honor Society 
Michael Froehlich, 
MSII
Jacob Rubin, MSII
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Explore Medical Research!
When I attended a seminar on  t he  e pid em iolo g y  of HIV infection and AIDS in Washington, D.C., chaired by 
Alan Greenberg, M.D. ’82, M.P.H., professor 
and chair of the Department of Epidemiology 
and Biostatistics at the George Washington 
University (GW) Milken School of Public 
Health, I didn’t know that it would be a 
life changing event, and lead me to move 
across the country from San Francisco and 
the University of California, San Francisco, 
to take up the chair of the Department 
Microbiology, Immunology, and Tropical 
Medicine (MITM) at GW in October 2013. 
The HIV epidemic in Washington, 
D.C., is extraordinary both in its magnitude 
and in the responses elicited to help turn it 
around. Black men who have sex with men 
living in the District still have a one in two 
chance of becoming HIV infected in their 
lifetime. The prevalence of HIV infection in 
Hispanic males and black females is around 
2  percent — well above epidemic levels. In 
other words, just from the steps of our nation’s 
government, an infectious disease epidemic 
of sub-Saharan proportions is occurring, 
and almost ignored. At the seminar, I saw 
that some groups in Washington were 
responding: the Department of Health, the 
National Institutes of Health (NIH), and 
GW through its developmental Center For 
AIDS Research (CFAR). That commitment 
from these groups, and others, inspired me 
to move to the East Coast, and to take up the 
position of chair at MITM. 
As both a physician and a scientist, I 
am often asked what the research part 
of my job entails. I think of myself as 
studying “experimental medicine,” which 
the British Medical Research Council refers 
to as: “Investigation undertaken in humans, 
relating where appropriate to model systems, 
to identify mechanisms of pathophysiology or 
disease, or to demonstrate proof-of-concept 
evidence of the validity and importance of 
new discoveries or treatments.” I would add 
to this that valid animal models are extremely 
valuable in advancing scientific knowledge, 
but for my research they need to support what 
we are doing in human studies. Our studies 
usually start at the bench, but in some cases 
then can go into experimental systems, and 
potentially even into humans. Our NIH 
funded grant, BELIEVE, one of the Martin 
Delaney Collaboratories to Cure HIV, under 
the leadership of Catherine Bollard, M.D., 
professor of pediatrics and of MITM at 
SMHS; Greenberg; Brad Jones, Ph.D., assis-
tant professor of MITM; and myself, plans for 
clinical trials of enhanced immunotherapy to 
eradicate HIV infection.
The MITM faculty at SMHS have long 
worked on infectious diseases of poverty, and 
HIV/AIDS is part of that mission, not only in 
a domestic context, but also internationally. 
Our faculty’s research spans basic through 
translational to clinical research, and is thus 
an ideal place for a medical student to experi-
ence the full spectrum of medical research. 
Basic science research is one of the most 
exciting activities you can do as a medical 
student, and the techniques learned for 
research pay off in expanding your thinking 
for patient diagnoses. The scientific method 
helps hone skills you will use with your 
patients. Essentially basic science can be like a 
diagnostic analysis: knowing the background 
of the literature, or the patient; developing 
a hypothesis, or differential diagnosis; run-
ning experiments, or tests; interpreting data, 
or test results; developing conclusions, or a 
patient treatment plan; and devising follow 
up experiments, or a patient follow-up plan.   
Our department also has strong pro-
grams in translational science. Research, for 
Our faculty’s research spans basic through translational to 
clinical research, and is thus an ideal place for a medical student 
to experience the full spectrum of medical research. 
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example, could involve anything from vali-
dating biomarkers for cancer or to addressing 
parasitic infections.
My Message to the SMHS students 
is simple, get involved. Apply for a Gill 
Fellowship; write and visit MITM (or other 
departments); read about the department’s 
research on the MITM website; come to 
our academic seminars and interest group 
meetings. 
Discover the excitement of scientific and 
medical research!
DOUGLAS NIXON, M.D., PH.D., professor and 
chair of microbiology, immunology, and trop-
ical medicine and Walter G. Ross Professor of 
Basic Science Research at SMHS
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Stimulation of protease-activated 
receptor 1 (PAR1) on endothelium by 
activated protein C (APC) is protec-
tive in animal models of inflamma-
tion, and APC has been used clinically 
in sepsis and wound healing. Clinical 
use of APC in sepsis, however, was 
terminated as it was compromised by 
APC’s anticoagulant activity, which 
is associated with bleeding and limits 
its dosing in patients.1 We used a small 
molecule approach to circumvent 
this problem. With support from 
the Molecular Libraries Program, we 
screened 302,457 compounds to iden-
tify small molecules that modulated 
PAR1-mediated platelet activation. 
One class of PAR1-targeted com-
pounds, which we termed parmodu-
lins, was found to act at the cytosolic 
face of PAR1, at the G-protein binding 
sites. When evaluated in endothelial 
cell cultures, parmodulin 1 (PM1) and 
parmodulin 2 (PM2) inhibited apop-
tosis induced by thrombin, TNF-α, 
or staurosporine, in a manner similar 
to APC.2 PAR1 knockdown using 
siRNA abolished these protective 
effects, demonstrating that parmodu-
lins elicit a cytoprotective pathway by 
acting through PAR1. 
To assess the mechanism of action 
of parmodulin cytoprotection, we 
first evaluated proximal signaling 
mechanisms. Parmodulins stimu-
lated phosphorylation of PI3-kinase 
and Akt in endothelium. Inhibition 
of Gβγ blocked parmodulin-induced 
phosphorylation of Akt, indicating 
that parmodulins act at the cyto-
solic face of PAR1 by releasing Gβγ. 
Transcriptional profiling of over 
30,000 genes and specific evaluation 
of NF-κB transcriptional activation 
showed that exposure to PM2 blocked 
TNF-α-induced transcriptional 
activation. In addition to interfering 
with inflammatory signaling, par-
modulins stimulated the upregulation 
of cytoprotective proteins such as 
stanniocalcin-1. 
Since our premise was that par-
modulins could achieve cytoprotec-
tive effects without anticoagulant 
effects, we compared dose curves of 
APC versus PM2 in both apoptosis 
assays and standard clotting assays. 
APC prolonged the aPTT at concen-
trations lower than those required 
to achieve cytoprotection of the 
endothelium. The low APC concen-
tration used in our study was similar 
to plasma concentrations measured 
in clinical studies. Hence, these data 
were consistent with the fact that 
clinical bleeding was observed at 
doses of APC used for sepsis. In con-
trast, despite inhibiting apoptosis as 
effectively as APC, PM2 had no effect 
on plasma aPTT at any concentration. 
Nonetheless, PM2 was able to inhibit 
lipopolysaccharide (LPS) and tumor 
necrosis factor-α (TNF-α) induced 
thrombin generation and FXa acti-
vation on endothelium owing to its 
cytoprotective effect. 
PM2 also prevented TNF-α-
induced accumulation of platelets 
on endothelium in bioengineered 
microvessels. These data demonstrate 
that PM2 can reduce inflammation-
induced endothelial pro-thrombotic 
phenotype even without directly 
inhibiting coagulation factors. To 
assess the endothelial protective 
effects of PM2 in vivo, we evalu-
ated leukocyte rolling in cremaster 
venules of mice. Infusion of PM2 
significantly reduced surgery-induced 
leukocyte rolling f lux compared 
to vehicle-treated mice. We also 
monitored soluble E-selectin levels in 
LPS-induced inflammation because 
these selectins are critically involved 
in leukocyte rolling. Treatment of 
mice with PM2 significantly reduced 
the LPS-induced release of soluble 
E-selectin. Previously, we demon-
strated that PM2 blocked platelet 
accumulation in a mouse laser injury 
model of thrombus formation. We 
now show that infusion of PM2 also 
significantly reduces fibrin accumula-
tion to 25 percent of control (p<0.001) 
at the site of laser injury.    
Together, our data indicate that 
PM2 exerts endothelial-mediated 
anti-inflammatory, anti-coagulant 
and anti-thrombotic effects in vitro 
and in vivo. These results demonstrate 
the utility of modulating PAR1 at the 
cytosolic face and could represent an 
alternative approach to APC in the 
treatment of thromboinflammatory 
disorders like sepsis.
REFERENCES
1. Griffin JH, Zlokovic BV, Mosnier LO. 
Activated protein C: Biased for translation. 
Blood. 2015;125(19):2898-2907.
2. A isiku O, et a l . Pa rmodu lins in h ibit 
thrombus formation without inducing 
endothelial injury caused by vorapaxar. 
Blood. 2015;125(12):1976-1985.
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BACKGROUND: Successful eradication 
of chronic hepatitis C virus (HCV) 
relies on effective screening programs 
for early detection and linkage to 
care. However, awareness of HCV 
screening guidelines may be lacking, 
especially among urban safety-net 
populations with a high prevalence 
of socioeconomically disadvantaged 
non-English speaking minorities.
AIM: To evaluate rates of HCV 
screening and HCV awareness among 
patients at high risk for chronic HCV 
at a diverse safety-net hospital
METHODS: A prospective cohort 
study of consecutive adults under-
going outpatient endoscopy from 
July 2015-March 2016 evaluated HCV 
screening rates among high-risk 
patients (based on U.S. Preventative 
Ser vices Task Force guidelines), 
with focus on birth cohort (1945–65) 
and risk-based (history of drug use, 
incarceration, blood transfusion prior 
to 1992) factors. Awareness of prior 
HCV results and rates of accepting 
HCV testing were evaluated with 
chi-square testing and multivariate 
logistic regression.
RESULTS: Among 869 patients, 
65.5% (n=569) were high risk for 
chronic HCV (51.3% male, 57.8% 
1945-1965 birth cohort, 4.5% history 
of drug use, 6.2% history of incar-
ceration, 5.8% blood transfusion, 
9.8% HIV).  Among this cohort, 
30.6% received prior HCV testing, of 
which 36% were aware of test results. 
HCV-positive patients were more 
likely than HCV negative patients 
to be aware of results (90% vs. 27.7%, 
p<0.001). Among high-risk patients 
offered HCV testing, 83.9% accepted. 
Compared to non-Hispanic whites 
(64%), blacks (80.6%), Asians (89.6%), 
and Hispanics (93.7%) were more 
likely to accept testing, p<0.001. 
Non-English speaking patients were 
more likely to accept testing (91% 
vs. 77.5%, p<0.001). Patients born in 
1945-1965 were less likely to accept 
testing (82.6% vs. 91.9%, p=0.06). 
On multivariate regression, blacks, 
Asians, and Hispanics were all sig-
nificantly more likely to accept HCV 
testing compared to non-Hispanic 
whites (Table).
CONCLUSION: Among adults pre-
senting for outpatient endoscopy at 
an urban safety-net hospital, 65.4 
percent were high risk for HCV, of 
which only 30.6 percent received 
prior testing. Of those who received 
prior testing, only 36 percent were 
aware of results. Lower rates of test 
acceptance among the 1945–65 birth 
cohort is concerning given higher 
risks among this group.
REFERENCES
1. Turner BJ, Taylor BS, Hanson JT, et al. 
Implementing hospital-based baby boomer 
Hepatitis C virus screening and linkage to 
care: Strategies, results, and costs. J Hosp 
Med. 2015;10(8):510-6.
2. Falade-Nwulia O, Mehta SH, Lasola J, et 
al. Thomas DL. Public health clinic-based 
Hepatitis C testing and linkage to care in 
Baltimore. J Viral Hepat. 2016;23(5):366-74.
3. Mil ler LS, Roll in F, Fluker SA, et a l. 
High-yield birth-cohort Hepatitis C virus 
screening and l inkage to care among 
underserved African Americans, Atlanta, 
Georgia, 2012-2013. Public Health Rep. 
2016;131 Suppl 2:84-90.
TABLE: Multivariate Logistic Regression Predicting Acceptance  
of HCV Testing
OR 95% CI P-Value
Male (vs. female) 1.61 0.86–3.01 0.13
1945–65 Birth cohort 0.34 0.10–1.19 0.09
Non-Hispanic white 1.00 Reference — 
Black 2.59 1.21–5.54 0.01
Asian 5.80 2.26–14.91 < 0.001
Hispanic 10.93 4.41–27.10 < 0.001
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Somatic mutations affecting ETV6 
often occur in acute lymphoblastic 
leukemia (ALL), the most common 
childhood malignancy. Inherited 
mutations of transcription factors 
have also recently been associated 
with susceptibility to acute leukemia. 
However, the genetic factors that pre-
dispose to ALL remain poorly under-
stood. Here, we report two unrelated 
kindreds with inherited mutations in 
ETV6, the gene encoding the tran-
scription factor ETS variant 6. These 
families were characterized by a low 
platelet count (thrombocytopenia) 
and ALL. Sequencing a panel of genes 
identified germline ETV6 mutations 
associated with leukemia and throm-
bocytopenia in multiple individuals 
tested. We identify a novel germline 
ETV6 p. L349P mutation in a kin-
dred affected by thrombocytopenia 
and ALL (Kindred 1, Figure 1). A 
second ETV6 p. N385fs mutation was 
identified in an unrelated kindred 
characterized by thrombocytopenia, 
ALL, and secondary myelodysplasia/
acute myeloid leukemia (Kindred 
2, Figure 1). Leukemic cells from 
the proband in the second kindred 
showed deletion of wild type ETV6 
with retention of the ETV6 p. N385fs. 
Enforced expression of the ETV6 
mutants revealed normal transcript 
and protein levels, but impaired 
nuclear localization. Accordingly, 
these mutants exhibited significantly 
reduced ability to regulate the tran-
scription of ETV6 target genes. Our 
findings highlight a novel role for 
ETV6 in leukemia predisposition.
ETV6 encodes an ETS family 
transcription factor that is frequently 
rearranged or fused with other genes 
in human leukemias of myeloid or 
lymphoid origin.1 Also known as the 
TEL oncogene, ETV6 is a sequence-
specific transcriptional repressor, 
regulated by auto-inhibition and 
self-association.2,3 Descriptions of 
ETV6 largely focus on the ETV6/
RUNX1 fusion, which is a product of 
a t(12;21) chromosomal translocation, 
the most common genetic abnor-
mality in pediatric ALL.4 While 
somatic deletions or mutations in 
ETV6 are increasingly recognized in 
ALL, nothing is known regarding the 
impact of germline ETV6 mutations.5 
Here, we extend the description of 
the clinical phenotype and functional 
effects associated with novel germ-
line ETV6 L349P and ETV6 N385fs 
mutations, both of which reside in the 
highly conserved ETS DNA binding 
domain and co-segregate with disease 
in two unrelated kindreds affected by 
thrombocytopenia and ALL.
These findings suggest that germ-
line ETV6 mutations cause a new 
type of heritable leukemia. This 
discovery makes possible the pre-
symptomatic diagnosis of leukemia 
susceptibility in families with germ-
line ETV6 mutations and also pro-
vides new information on the causes 
of leukemia.
REFERENCES
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2010;285:18496-18504. doi: 10.1074/jbc.
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Synthetic cannabinoids (SCs), also 
known as “K2” or “Spice,” are the 
second most common drugs of abuse 
after marijuana.3 These synthetic 
chemicals are typically sprayed on 
plant material, which is then most 
commonly smoked or ingested, 
providing a relaxing and stimulating 
effect. The adverse effects of SC 
toxicity are heterogeneous and can 
include anxiety, agitation, emesis, 
hallucinations, convulsions, psy-
chosis, tachycardia, and unrespon-
siveness.2 Serious systemic effects 
include stoke, renal failure, myocar-
dial infarction, respiratory failure, 
and death.1 In 2015, the American 
Association of Poison Control 
reported that SC cases had increased 
by 562 percent from March to April 
of that year. In May 2015 alone, more 
than 40 deaths in the United States 
were associated with SC use.1
SC abuse is a growing and serious 
public health concern that demands 
f u r ther cl i n ica l  i nvestigation, 
increased public education, as well as 
further legislative and drug enforce-
ment efforts. Previous research has 
focused on presentation and out-
comes of patients who were reported 
to poison control centers or admitted 
to the emergency department (ED).4 
Other studies documented signifi-
cant differences between SCs and 
traditional marijuana, with agitation, 
neurotoxicity, and cardiotoxicity 
more pronounced in patients who 
used SCs.5 Despite well-documented 
severe effects of SC use, literature 
regarding the hospital course and 
outcomes after SC intoxication is 
scarce. Further research is necessary 
to improve physician understanding 
of the potential harmful effects of SC 
use and to identify patients at greatest 
risk for adverse outcomes. This study 
characterizes the clinical presenta-
tion and hospital course of patients 
with reported SC exposure requiring 
Intensive Care Unit (ICU) admission.
A retrospective case series was 
done of patients admitted to the 
medical or cardiac ICUs of an urban 
tertiary care center with reported SC 
exposure from Jan. 1 to Dec. 31, 2015. 
Demographic variables, Sequential 
Organ Failure Assessment (SOFA) 
scores, clinical parameters docu-
menting the effects, and hospital 
course were recorded. 
Twenty-three patients met inclu-
sion criteria. Median age was 47 
(Inter-Quartile Range [IQR], 32-54); 
82.6% were male; 78.3% were black. 
Patients were most commonly tachy-
cardic (56%) and hypertensive (65%) 
on admission; none were febrile. 
The initial chest X-ray and electro-
cardiogram were abnormal in 43.4% 
and 68.4% of patients respectively. 
Myocardial infarction occurred in 
8.7%, resulting in heart catheteriza-
tion. Brain imaging was abnormal in 
5% of patients. The most common 
concomitant exposures were mari-
juana (30.4%) and benzodiazepines 
(26.1%).
SOFA scores peaked on admission 
at 6 and decreased over the next three 
days, rising thereafter for patients 
requiring continued ICU care. SOFA 
scores were primarily driven by 
altered neurologic status and respi-
ratory failure. Over 30% of patients 
had seizures as a part of presentation, 
91% required mechanical ventilation, 
18.2% required vasopressors, and 5% 
needed dialysis. Other invasive pro-
cedures included central and arterial 
lines (8.7%), lumbar puncture (4.3%), 
and heart catheterization (8.7%). 
Median hospital and ICU lengths 
of stay were 2.6 (IQR 1.4-3.5) and 1.6 
(IQR 0.9-2.5) days, respectively. The 
mean hospital charge was $49,140. 
All patients survived the index hospi-
talization with one patient dying on 
a subsequent hospitalization during 
the study period.    
In conclusion, synthetic canna-
binoid exposure can result in serious 
adverse effects and significant organ 
dysfunction, particularly neurologic 
and respiratory. While generally non-
fatal, successful treatment requires a 
high degree of complexity and cost.
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BACKGROUND: The prevalence of obe-
sity in the United States (U.S.) among 
adult men and women continues 
to rise. Obesity is a major health 
problem among the U.S. population, 
commonly increasing the risk of sig-
nificant comorbidities such as Type 2 
diabetes mellitus, dyslipidemia, and 
cardiovascular diseases.1,2 While 
in-person interventions that address 
the dietary, exercise, and behavioral 
aspects of obesity are common, a 
new wave of weight-loss strategies 
has emerged with a greater emphasis 
on technology and internet-based 
approaches.3,4,5
METHODS: This study compared 
the efficacy of a traditional in-person 
weight-loss approach utilized by the 
Johns Hopkins Weight Management 
Center to a weight-loss treatment via 
the smartphone application (app), 
LoseIt! It was hypothesized that 
the comparison between the Johns 
Hopk ins Weig ht Ma na gement 
Center protocol and the LoseIt! App 
program over a 12-week period would 
show no difference in the percent 
of actual weight loss compared to 
theoretical weight loss, i.e. compli-
ance. Using a case-control analysis, 92 
Johns Hopkins patients were matched 
to 3,380 LoseIt! App participants 
based on gender, age, starting weight, 
starting BMI, caloric restriction level, 
and estimated total daily energy 
expenditure with light activity.
RESULTS: Clinic patients achieved 
94.1% of their theoretical weight 
loss compared to LoseIt! users who 
achieved 62.8% after matching. In 
addition, clinic patients achieved 
10.5% total weight loss compared 
to LoseIt! users who lost 6.1% after 
matching. Overall, clinic patients 
showed a significantly greater percent 
FIGURE:  Descriptive Information from Matched Participants Before 
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TABLE 1:  Descriptive Information from Matched Participants Before 
Analysis
of realized theoretical weight loss or 
compliance (mean = 28.6, SD = 9.6, p 
> 0.003) compared to LoseIt! users. 
Moreover, clinic patients showed a 
significantly greater percent of total 
weight loss (mean = 3.2, SD = 0.9, p > 
0.001) compared to LoseIt! users.
DISCUSSION: While weight loss 
programs are ubiquitous, historically, 
long-term compliance to these pro-
grams is often limited. We found that 
both clinic-based and technology-
based weight-loss programs provided 
a degree of weight-loss success when 
participants are matched for demo-
graphic and biologic characteristics. 
These findings suggest that appli-
cation-based weight-loss programs 
may have a place in weight control. 
However, as shown here, they may 
not be as efficacious as a clinic-based 
intervention. Nonetheless, this tech-
nology may be particularly helpful as 
a cost-effective means for influencing 
patient dietary and exercise behav-
iors. Future studies should examine 
whether smartphone applications like 
LoseIt! would produce an additive 
benefit when used in combination 
with more traditional approaches to 
weight control.
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Characteristics
Clinic N = 92 
n (%)
LoseIt!  
N = 3,380 P value
Gender 0.51
   Female 71 (77) 2,505 (74)
    Male 21 (23) 875 (26)
Age < 0.001
    21–30 8 (9) 727 (21)
    31–40 11 (12) 883 (26)
    41–50 33 (36) 693 (21)
    51–60 33 (36) 693 (21)
    61–70 7 (7) 213 (6)
Age at first day, mean (SD) 48.0 (10.0) 41.7 (11.8) < 0.001
Start weight, mean (SD) 240.7 (51.8) 201.6 (44.9) 0.001
First BMI, mean (SD) 38.3 (7.1) 31.9 (6.2) < 0.001
First BMI, category 0.001
    Overweight 8 (9) 1,492 (44)
    Obesity I 28 (30) 1,018 (30)
    Obesity II 21 (23) 512 (15)
    Extreme obesity 35 (38) 358 (11)
Calorie restriction plan, mean (SD) 1,131 (244) 1,513 (337) <0.001
Calorie restriction plan (kcal) <0.001
    0–750 0 (0) 8 (0)
    750–1,250 78 (85) 775 (23)
    1,250–1,750 10 (11) 1,747 (24)
    2,250–2,750 0 (0) 34 (1)
Daily energy expenditure, light activity, 
mean (SD)
2,454 (414) 2,261 (390) <0.001
Light activity energy expenditure (kcal) <0.001
    1,500–2,000 10 (11) 1,054 (31)
    2,000–2,500 43 (47) 1,365 (40)
    2,500–3,000 31 (34) 821 (24)
    3,000–3,500 7 (8) 135 (4)
    3,500–4,000 1 (0) 5 (1)
Percent of theoretical weight loss 
achieved, mean (SD) 
91.4 (68.4) 80.1 (526.8) 0.84
Percent of weight loss, mean (SD) 10.5 (4.5) 6.1 (4.7) < 0.001
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Guidelines suggest annual screening 
for depressive symptoms in pediatric 
diabetes care.1 Depressive symptoms 
are associated with poorer glycemic 
control2 and may contribute to the 
decline in diabetes self-care seen 
in adolescents and young adults 
(AYA) with Type 1 diabetes (T1D).1 
Depressive symptoms also may influ-
ence AYA interaction with their dia-
betes care provider. Understanding 
relationships between depressive 
symptoms and health care interac-
tions will inform optimal diabetes 
care for this age group. 
Our overarching goal was to eval-
uate depressive symptoms in AYA 
with T1D; we did this in two ways, 
using both clinically derived data and 
data from an ongoing longitudinal 
study. The Child and Adolescent 
Diabetes Program at Children’s 
National Health System implemented 
routine physician-directed depres-
sion screening for all youth aged ≥ 13 
years. We evaluated this clinic-based 
screening process as part of overall 
quality improvement, and analyzed 
baseline data from the ongoing study 
to identify relationships between 
depressive symptoms, interactions 
with health care providers, and gly-
cemic control. 
In clinic-based screening efforts, 
adolescents completed the Patient 
Health Questionnaire-9 modified 
for Adolescents (PHQ 9-A) at a rou-
tine clinic visit (Table 1). Through 
inter views, al l providers agreed 
clinic-based depression 
screening was valuable 
and easy to implement. 
Areas for improvement 
i nc l ud e d  s c r e en i n g 
y o u n g e r  p a t i e n t s , 
streamlining adminis-
trative procedures, and 
integrating screens with 
the electronic medical 
record. 
Participants (n = 76) in the longitu-
dinal study completed the Center for 
Epidemiological Studies Depression 
Scale (CES-D); scores ≥ 16 are con-
sidered at risk for depression. Clinic 
visits were audio-recorded. Quality of 
communication was coded using the 
Roter Interactional Analysis System 
(RIAS), which generated a measure 
of patient-centered communication 
(PCC). Participants rated their inter-
actions with their health care provider 
during the clinic visit using the 
Health Care Climate scale (HCC). 
Hemoglobin A1c (HbA1c) values were 
extracted from medical records.
Results (Table 2) indicate that 
28.9% of this sample were at risk 
for depression. CES-D scores were 
directly associated with HbA1c (r(74) 
= 0.232, p < 0.05) and PCC (r(67) = 
0.343, p < 0.01). There was no sig-
nificant association between CES-D 
score and AYA HCC score. AYA 
HCC score was negatively correlated 
with HbA1c (r(72) = -0.295, p < 0.05). 
PCC was not significantly associated 
with HbA1c. 
Our data suggest that depressive 
symptoms are relatively prevalent 
in AYA with T1D and are associated 
with glycemic control, reinforcing 
the importance of routine depres-
sion screening in this population. 
Improved detection of depressive 
symptoms may reduce diabetes com-
plications; however, incorporating 
screening procedures into a busy 
clinic requires cooperation from 
providers, administrative staff, and 
the psychology team. As evidenced by 
provider interviews, to achieve such 
cooperation, those involved must 
understand their roles and feel sup-
ported, and policies and procedures 
must be periodically reviewed and 
revised. 
We have shown that depressive symptoms 
are associated with HbA1c and PCC in AYA; 
however, the causality underlying these rela-
tionships is not yet understood.
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TABLE 1: PHQ 9-A Results in 
Clinic-Based Screening
Number of screens 514
Mean score 4.08
Score range 0–26
Moderate depressive 
symptoms
11.59%
Severe depressive symptoms 1.27%
Current suicidal ideation 6.72%
Depressive Symptoms and the Health Care 
Experience of Adolescents with Diabetes
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TABLE 2: Demographic Information and Study Results 
Elevated depressive symptoms 
were associated with greater PCC, 
suggesting that providers might have 
responded to patient mood by encour-
aging active participation during the 
clinic visit to both gather informa-
tion and increase engagement. This 
finding differs from studies with 
adults, which have found no differ-
ence in PCC based on patient depres-
sive symptoms. 
Further study is needed to more 
fully understand the complex asso-
ciations among mood and health 
communication, and how the pro-
vider relationship may contribute to 
overall positive health outcomes. We 
have shown that depressive symp-
toms are associated with HbA1c and 
PCC in AYA; however, the causality 
underlying these relationships is not 
yet understood. Elucidating this 
will inform development of future 
interventions.
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%
Participant sex (% female) 53.9
Insulin pump use 32.1
Basal bolus regimen 33.3
Fixed dose insulin therapy 34.6
White, non-Hispanic 50.0
Racial minorities 42.1
No race/ethnicity reported 1.3
Annual family income ≥ $100,000 56.7
Range Mean SD
Participant age (years) 16–20 17.77 1.22
Duration of diagnosis (years) 1.22–18.55 8.20 4.41
HbA1c (%) 5.6–14.1 8.20 4.41
CES–D score 0–44 13.11 9.80
Clinic visit length (min) 2.63–48.98 21.28 10.12
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Mental health disorders have been 
identif ied as some of the most 
common clinical manifestations 
American military veterans face, 
affecting up to 25 percent of veterans 
at rates that are higher than those of 
their civilian counterparts.1 Given 
the odds of veterans developing a 
mental illness, it is important for 
health care professionals to attempt 
an understanding of how they make 
sense of their illness experiences. 
One of the major ways humans make 
sense of their experiences is through 
the telling of narratives. Narratives 
are a crucial tool for making sense 
of life experiences and for under-
standing ourselves and others.2,3,4 It is 
fortuitous for us then that medicine 
involves stories. 
Using a grounded theory approach, 
the present study conducted constant 
comparative analysis, wherein similar 
and dissimilar data are first identi-
fied and then compared in order to 
generate knowledge about common 
patterns and themes within human 
experience. It is important to note 
that this approach does not involve 
coding narrative variables as some 
qualitative methodologies demand, 
but rather the interpretation of 
themes in the narratives. The 165 
narratives examined in this paper 
were collected by third-year medical 
students during their inpatient medi-
cine clerkship at the DC VA Medical 
Center (described in Chretien et al., 
2015).5 
Researchers selected narratives 
for inclusion if they contained partic-
ular words related to mental health. It 
is interesting to first note with what 
frequency veteran patients sponta-
neously shared their experiences of 
mental health, especially while on 
a general medicine unit (see Table). 
In fact, one recurring theme among 
mental health narratives was the 
complicated relationship between 
physical and mental illness. One 
patient describes his experience with 
COPD, CHF, diabetes, and anxiety: 
“Trying to balance all of these is a 
challenge … . Meanwhile the anxiety 
overlays all of it and makes it harder” 
(049). Another student recognizes 
this complexity in his patient’s nar-
rative: “He tells me that he has suf-
fered from depression the last couple 
of years, and to me it sounds like 
both his diabetes and depression are 
strongly linked” (112). 
Results suggest that veterans 
generally avoided sharing details 
of their PTSD diagnoses, except 
when describing their nightmares 
TABLE: Frequency of Narratives that Contained Mental Health Themes
* total narratives = 165
Frequency Percentage of MH Percentage of Total *
Mental health 42 — 25.5
   Anxiety 5 11.9 3.0
   Depression 7 16.7 4.2
   PTSD 8 19.0 4.8
   Substance use 23 54.8 13.9
   Suicidal ideation 8 19.0 4.8
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except when describing their nightmares or instances of moral injury, 
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or instances of moral injury, defined 
as actions taken by veterans in the 
line of duty that transgress deeply 
held moral beliefs and expectations. 
Substance use was the most com-
monly mentioned mental health con-
dition. Many patients attributed their 
physical illness to their substance use; 
others attributed their substance use 
to their illness. Suicidal ideation was 
endorsed by 4.8 percent of the nar-
rative authors and was most often 
in the form of passive death wishes. 
Patients also shared the things that 
deterred them from abusing drugs 
and alcohol and from taking their 
own lives, important potential points 
of intervention. 
Using veterans’ personal nar-
ratives as the primary data source, 
this paper has identified common 
themes regarding mental health 
among military veterans to better 
prepare health care professionals to 
recognize and treat mental illness in 
this at-risk population. This investi-
gation expands on a body of knowl-
edge gathered qualitatively about the 
mental health needs of our military 
veterans. This knowledge, gained 
by simply allowing patients to share 
their personal narratives, allows us 
to better understand and thus serve 
their health care needs. The impor-
tance of narrative medicine, as both a 
tool for research and therapy, cannot 
be understated.
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OBJECTIVES: Our objective was to 
compare the rates at which HIV, 
malaria, and TB affect pregnancy 
outcomes in the United States using 
national data from the Healthcare 
Cost and Utilization Project (HCUP) 
National Inpatient Sample (NIS). 
ME THODS:  We ex plored d if-
ferences in pregnancy outcomes 
between patients with HIV, malaria, 
and TB diagnoses and compared 
patterns in outcomes over time, 
focusing on the following two study 
cycles: 1998–2000 and 2009–11. 
We also compared the outcomes 
of these patients to those pregnant 
without these diagnoses. We identi-
fied pregnancy hospitalizations that 
resulted in delivery, as well as preg-
nancy outcomes, using the appro-
priate International Classification 
of Disease, Ninth Revision (ICD-9), 
and V codes. Statistical weighting 
of the data produced samples that 
were nationally representative. SAS 
software and chi-square testing was 
used to determine p-values.
RESULTS: Overall, there were more 
cases of HIV, followed by TB, then 
malaria in pregnancy in both time 
periods. Women with HIV were more 
likely to be younger (5.2% vs 6.8% age 
0-20; p<0.05) in the later time period. 
Cesarean delivery was more likely for 
HIV pregnant women in the later time 
period (57.9% vs. 44.3%; p<0.0001) but 
the odds ratio for undergoing cesarean 
delivery compared to controls was 
comparable during both time periods 
(OR 2.86 vs. 2.84). Complications 
such as other infections in pregnancy 
(sexually transmitted infections or 
urinary tract infections) were less 
likely in the later time period for 
women with HIV. In the later years, 
patients with TB were significantly 
more likely to experience comorbid 
diabetes, fetal distress, preterm labor, 
and urinary tract infections than the 
control group.
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TABLE 1A: Pregnancy Complications of Infectious Disease Patients vs. Control Group During Early and Late 
Time Periods, 1998–2000
CONCLUSIONS: The adverse out-
comes studied here are much more 
common among patients with infec-
tious disease, especially those with 
HIV. Although the prevalence of 
 Continued from p. 13 cesarean delivery among women 
with HIV has gone up over time, 
the odds ratio compared to controls 
has not changed from early to late 
time period. Infectious disease 
patients under obstetric care require 
continued comprehensive care in 
order to prevent adverse outcomes 
in pregnancy.
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1998–2000
Complication
HIV  
(n=3,803)
OR  
(95% CI)
P
Malaria 
(n=144)
OR  
(95% CI)
P
TB 
(m=727)
OR (95%CI) P
Control  
(n=11 967 
487)
Cesarean delivery
1,649  
(43.7%)
2.84  
(2.45, 3.29)
<0.001
41 
(29.1%)
1.50  
(0.66, 3.41)
0.3
216 
(30.9%)
1.63  
(1.14, 2.34)
0.01
520 908  
(21.5%)
Diabetes 
(comorbidity)
60  
(1.6%)
2.39  
(1.35, 4.23)
0.002 — 10 (1.5%)
2.22  
(0.55, 8.99) 
0.25 16 246 (0.7%)
Fetal distress
32  
(0.9%)
0.45  
(0.20, 1.02)
0.05 — 15 (2.1%)
1.12  
(0.35, 3.56)
0.85 45 566 (1.9%)
Gestational 
diabetes
111  
(2.9%)
0.83  
(0.53, 1.28)
0.39
11 
(8.0%)
2.38  
(0.56, 
10.04)
0.2 35 (5.0%)
1.43  
(0.67. 3.07)
0.36 85 293 (3.5%)
Hypertension 
(comorbidity)
60  
(1.6%)
3.04  
(1.72, 5.39)
<0.0001 — 12 774 (0.5%)
Intrauterine fetal 
death
69  
(1.8%)
3.034  
(1.78, 5.15)
<0.0001 — — 14 810 (0.6%)
Liver disorders of 
pregnancy
27  
(0.7%)
12.71  
(5.26, 30.73)
<0.0001 — — 1,358 (0.1%)
Premature 
Rupture  
of Membranes
369  
(9.8%)
1.72  
(1.35, 2.20)
<0.0001 — 64 (9.0%)
1.61  
(0.91, 2.86)
0.01
142 737 
(5.9%)
Pre-eclampsia
234  
(6.2%)
1.86  
(1.38, 2.51)
<0.0001
10 
(7.4%)
2.24  
(0.53, 9.45)
0.3 26 (3.8%)
1.10  
(0.45, 2.70)
0.84 82 609 (3.4%)
Preterm labor
599  
(15.9%)
2.61  
(2.14, 3.18)
<0.0001
22 
(15.5%)
2.52  
(0.87, 7.29)
0.1
90 
(12.9%)
2.05  
(1.24, 3.36)
0
162 435 
(6.8%)
Sexually 
transmitted 
infections
105  
(2.8%)
18.14  
(11.60, 
28.38)
<0.0001 — — 3,737 (0.2%)
Urinary tract 
infection
352  
(9.3%)
2.97  
(2.31, 3.82)
<0.0001
15 
(10.9%)
3.54  
(1.06, 
11.74)
0 49 (7.0%
2.17  
(1.14, 4.41)
0.02 80 179 (3.3%)
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TABLE 1B: Pregnancy Complications of Infectious Disease Patients vs. Control Group During Early and Late 
Time Periods, 2009–11
2. Thompson JL, Kuklina EV, Bateman BT, 
et al. Medical and obstetric outcomes 
among pregnant women with congenital 
heart disease. Obstetrics & Gynecology. 
2015;126(2):346-354.
2009–11
Complication
HIV 
(n=3,401)
OR  
(95% CI)
P
Malaria 
(n=152)
OR 
(95% CI)
P
TB 
(m=723)
OR 
(95%CI)
P
Control  
(n=12 173 
217)
Cesarean delivery
1,959 
(57.7%)
2.86 
(2.45, 3.32)
<0.001
10 
(32.9%)
1.03 
(0.48, 2.19)
0.9
231 
(32.2%)
0.99(0.70, 
1.41)
0.98
797 124 
(32.3%)
Diabetes 
(comorbidity)
79  
(2.3%)
2.15 
(1.31, 3.54)
0.002 —
23 
(3.1%)
2.92 
(1.19, 7.21) 
0.01 27 054 (1.1%)
Fetal distress
54 
(1.6%)
0.76 
(0.42, 1.39)
0.38 —
34 
(4.7%) 
2.34 
(1.09, 5.02)
0.02 50 934 (2.1%)
Gestational 
diabetes
175 
(5.2%)
0.86 
(0.62, 121) 
0.39 —
33 
(4.7%)
0.78 
(0.36, 1.66)
0.51
146 407 
(5.9%)
Hypertension 
(comorbidity)
90 
(2.7%)
4.73 
(2.99, 7.47)
<0.001 — — 14 139 (0.6%)
Intrauterine fetal 
death
48 
(1.4%)
2.47 
(1.32, 4.62)
0.004 — — 14 421 (0.6%)
Liver disorders of 
pregnancy
43 
(1.3%)
9.27 
(4.78, 17.96)
<0.0001 — — 3,389 (0.1%)
Premature 
rupture of 
membranes
239 
(7.1%)
1.42 
(1.05, 1.91)
0.02 —
24 
(3.4%)
0.65 (0.27, 
1.60)
0.35
125 217 
(5.1%)
Pre-eclampsia 218 (6.4%)
1.54 
(1.14, 2.09)
0.005
14 
(9.3%)
2.29 
(0.70, 7.55)
0.2
19 
(2.6%)
0.615 (0.22, 
1.65)
0.32
105 201 
(4.3%)
Preterm labor
549 
(16.2%)
2.55 (2.08, 
3.13)
<0.0001 —
86 
(11.9%)
1.79  
(1.08, 2.98)
0.02
173 551 
(7.0%)
Sexually 
transmitted 
infections
86 (2.5%)
14.90 (9.19, 
24.17)
<0.0001 — — 4,299 (0.2%)
Urinary tract 
infection
212 (6.3%)
4.72 (3.45, 
6.45)
<0.0001 —
14 
(5.5%)
4.13 
(2.02, 8.43)
<0.0001 34 351 (1.4%)
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TABLE 1: Median OS, RT vs No Treatment, Stratified by Age
95% Confidence Interval
Age RT given? Estimate Lower Bound Upper Bound
60-64y No 6.000 5.442 6.558
Yes 12.000 11.333 12.667
Overall 9.000 8.577 9.423
65-69y No 5.000 4.544 5.456
Yes 11.000 10.396 11.604
Overall 8.000 7.604 8.396
70-74y No 4.000 3.662 4.338
Yes 10.000 9.450 10.550
Overall 6.000 5.678 6.322
75-79y No 3.000 2.711 3.289
Yes 9.000 8.476 9.524
5.705 6.295
80-84y No 2.000 1.782 2.218
Yes 8.000 7.421 8.579
Overall 4.000 3.709 4.291
85+y No 2.000 1.848 2.152
Yes 7.000 6.258 7.742
Overall 3.000 2.788 3.212
Overall 6.000 5.858 6.142
PURPOSE/OBJECTIVES: Stage 3B non-
small cell lung cancer (NSCLC) is 
very advanced and is traditionally 
considered a surgically unresectable 
disease. This is especially true for 
elderly patients (60-plus years of 
age), whose various comorbidities are 
contraindicative for surgery, leaving 
them with chemoradiation therapy 
in an attempt to contain disease 
and improve survival. The present 
literature has a dearth of research 
showing whether this aggressive 
therapy results in an improvement in 
overall or cause-specific survival, as 
compared with purely supportive care 
(no treatment). We hypothesize that 
stage 3B NSCLC patients of 60-plus 
years of age treated with radiation 
will have better overall survival (OS) 
and cause-specific survival (CSS) than 
those left untreated. 
METHODS: We selected 29,790 
patients of 60-plus years of age, diag-
nosed with stage 3B NSCLC between 
2002 and 2012, given either radiation 
therapy (RT) or no treatment from 
the Survival, Epidemiology and End 
Results Program (SEER) database. 
As SEER does not release chemo-
therapy data due to uncertainty 
regarding data completeness, such 
data were not included in our anal-
ysis. We conducted multivariable 
(Cox-proportional hazard) analysis, 
adjusting for age, race, sex, year of 
diagnosis, and tumor site, and uni-
variable (log-rank) analysis to eval-
uate the impact of RT on survival.
RESULTS: Forty-two and a half per-
cent of patients were given RT, while 
the remaining 57.5% were not treated. 
Patient median age range was 70 – 74 
years. The racial composition of the 
study population was 80.4% white, 
11.9% Black, 7.5% other race, .2% 
unknown race. Forty-four percent of 
patients were female, 56% were male. 
Distribution of tumor site within the 
population was 23.5% lower, 34.8% 
middle, and 47.2% upper lung, as well 
as 6.7% within the main bronchus, 
1.4% with overlapping lesion of the 
lung, and 17.8% NOS. Univariable 
analysis showed RT was associated 
with an improvement in median 
and five-year survival compared to 
no treatment. Median OS was 10 vs 
three months, and CSS was 11 vs four 
months in patients given RT vs those 
untreated (P<.0001). Five-year OS 
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was 7.8% vs. 2.4% of patients, and CSS 
was 11.2% vs. 3.8% in patients given 
RT vs. those untreated (P<.0001). 
Multivariable analysis showed better 
OS for those given RT with Hazard 
Ratio (HR) = 0.605 (95% CI = .59,.621, 
P<.0001), and better CSS with HR = 
0.606 (95% CI = .59,.623, P<.0001). 
Both median OS and CSS worsened 
with increased age, and RT improved 
survival in all age groups. 
CONCLUSION: The results of our 
univariable and multivariable anal-
yses suggest improvement in both 
OS and CSS for stage 3B NSCLC 
patients 60-plus years of age, given 
RT, as compared to no treatment. 
Approximately equal HRs for OS and 
CSS (.605 and 0.606, respectively) 
suggest the impact of confounding 
factors was insignificant. Our anal-
ysis was limited by absence of data 
on chemotherapy and comorbidities 
(SEER does not record). Further 
research ought to be done in the form 
of an RCT to confirm our findings. 
69.5 years, median = 12.9; 51% female). 
Fifty-four patients could not be con-
firmed and were excluded.  The most 
common manifestations were cogni-
tive/behavioral (42%), followed by 
CNS abnormalities (37%), plexiform 
neurofibromas (32%), MSK (21%), and 
other (19%).
A total of 13,643 outpatient pro-
vider visits occurred, with ophthal-
mology (18%) and oncology (23%) 
being the most frequent. Subjects 
underwent a total of 4,527 MRI scans; 
63% required sedation. Brain MRIs 
were the most common (N = 2,161). 
Treatment with prescription medica-
tions occurred in 13% of subjects for 
cognitive and behavioral disorders. 
Neurofibromatosis Type 1 (NF1) is an 
autosomal dominant tumor predispo-
sition syndrome occurring in 1:3,000 
births.1 Children with NF1 frequently 
develop manifestations affecting their 
central nervous system (CNS), mus-
culoskeletal (MSK) system, periph-
eral nervous system, and cognitive/
behavioral functions. Many of these 
manifestations persist throughout 
life, requiring multiple medical and 
surgical interventions, and have a 
significant impact on quality of life.2
The medical resource utilization 
and economic burden of caring for 
children with NF1 is unknown. Prior 
NF1 research has focused on specific 
manifestations that have inherent 
selection bias and do not accurately 
reflect the incidence and resource 
utilization of these morbidities. 
In order to identify which disease 
manifestations are in the most need 
of improved clinical algorithms and 
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novel therapeutics, the frequency and 
type of resources utilized (i.e. diag-
nostic imaging and specialty visits) 
must be determined. 
The current study sought to 
identify which manifestations of 
NF1 utilize the most health care 
resources and validate the accuracy 
of using International 
C l a s s i f i c a t i o n  o f 
Diseases, Ninth Revision 
(ICD-9) diagnostic codes 
to identify patients with a 
clinical diagnosis of NF1.
The electronic health 
record (EHR) at The 
Children’s Hospital of 
Philadelphia (CHOP) 
was queried to identify 
patients seen between 
J a n u a r y  2 0 1 1  a n d 
December 2015 whose 
visit contained the ICD-9 code 237.71. 
Subjects were excluded if the clinical 
or genetic diagnosis could not be 
confirmed.  For eligible subjects, 
the frequency of disease manifesta-
tions, MRI scans, and specialty visits 
over the five-year study period were 
recorded. The positive predictive 
value (PPV) of identifying subjects 
using the ICD-9 code was calculated. 
Nine-hundred-eleven subjects 
with NF1 were included (ages 0.7 to 
Understanding the economic costs of caring 
for children with NF1 will help identify oppor-
tunities to improve resource utilization and 
clinical care as well as encourage academic and 
industry institutes to partner in therapeutic 
development for this devastating disease.
 Continued on p. 18
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BACKGROUND: CT scans are widely 
used in U.S. emergency departments 
and represent a major source of carci-
nogenic radiation.1 Shared Decision 
Making (SDM) is the principle of 
including the patient in the decision 
process regarding diagnostic and 
therapeutic options. SDM has been 
used successfully in decisions such 
as hospital admissions for chest pain 
and surgery for appendicitis.2,3 It is 
unknown if shared decision-making 
is beneficial in the decision to order 
a CT scan in the emergency depart-
ment (ED). Our objective was to 
assess the desire of ED patients to 
participate in the decision process 
regarding CT scan use and describe 
differences in patients who want to 
participate versus those who do not 
want to participate. 
METHODS:  Patients who were 
receiving a CT scan in a tertiary care 
urban ED were approached from June 
to August 2016 and asked to partici-
pate in the study. If they verbally con-
sented, subjects were interviewed in 
the ED by a research assistant blinded 
to the objectives of the study after a 
CT scan had been ordered but prior 
to ED disposition. 
RESULTS: Of the 102 subjects who 
were enrolled, 58% were female, the 
median age was 46.5, and 48% received 
an abdominal CT scan. Forty-eight 
percent of all patients desired to 
“participate fully in the decision to 
perform CT scan,” compared to 44% 
who “did not want to participate in 
the decision to perform CT.” Of those 
who wanted to participate fully, there 
was no difference in median age, sex, 
type of CT, discussion of risks by phy-
sician, or explanation of alternatives 
by physician. Patients who wanted 
full participation were more likely to 
have concerns about CT scans (23% 
versus 11%, p=0.02) but also felt more 
involved in the decision process (31% 
versus 20%, p=0.04.)
CONCLUSION: Approximately 50 
percent of ED patients want to partic-
ipate in the decision to perform a CT 
scan and among those patients, they 
are more likely to have concerns about 
CT scans. There was no increase in 
discussion of risks or alternatives for 
patients who wanted to participate in 
the decision. 
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The 237.71 ICD-9 code accurately 
identified subjects with a confirmed 
diagnosis of NF1 (PPV = 94.4%) if the 
code was present once in the subject’s 
chart. The PPV increased to 98.2% 
if at least two subject visits included 
the code. 
To our knowledge, this is first 
study to describe the extent of med-
ical resource utilization, based on dis-
ease manifestation, in children with 
NF1. CNS manifestations required 
the highest frequency of MRI acquisi-
tions and specialty visits. The ICD-9 
code 237.71 accurately identified sub-
jects with NF1. 
Understanding the economic 
costs of caring for children with NF1 
will help identify opportunities to 
improve resource utilization and 
clinical care as well as encourage 
academic and industry institutes to 
partner in therapeutic development 
for this devastating disease.
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TABLE: Change in Management 
Modalities Based on Genetic 
Panel Results (N refers to number 
of patients that subsequently 
underwent a change in 
management or surveillance 
strategies based on a positive 
genetic mutation result from a 
specific genetic panel)
Clinical exam 64
Breast imaging 56
TVUS 48
TVUS with CA-125 46 
Colonoscopy 19
Endoscopic ultrasound 4
Thyroid ultrasound 2
Renal imaging 3
Endometrial sampling 6
EGD with duodenoscopy 9
Urinalysis 6
Neurology referral 8
Dermatology referral 49
Chemoprevention 17
Prophylactic surgery 46
Reproductive endocrinology 11
BACKGROUND: Since the Supreme 
Court ruling in 2013 against Myriad’s 
gene patent, a long w ith w ide-
spread adoption of next generation 
sequencing, panel testing for heredi-
tary cancer syndromes has expanded 
rapidly. Its practice has drawn criti-
cism due to concerns about the lack 
of clinical impact of testing results.
METHODS: A retrospective review 
was conducted of all patients pre-
senting to the Ruth Paul Hereditary 
Cancer Program at the George 
Washington University for genetic 
counseling and testing between Jan. 
2, 2015 and April 13, 2016. Outcomes 
of testing and clinical impacts of test 
results were recorded. Clinical man-
agement changes were based on cur-
rent National Comprehensive Cancer 
Network (NCCN) Guidelines.
RESULTS: Five hundred and twenty-
nine patients underwent genetic 
counseling for either a family or 
personal history of cancer or a known 
familial mutation. Of those coun-
seled, 81% (n=426) elected to undergo 
genetic testing ranging from single 
site (SS) analysis to 49-gene panels. 
Test selection was at the discretion 
of the certified genetic counselor. Of 
the tests, 4% (n=18) had SS, 0.5% (n=2) 
had single gene (SG), 13% (n=54) had 
testing limited to BRCA, and 83% 
(n=352) had panel testing. Of those 
tested, 18% (n=75, two individuals had 
more than one mutation) were found 
to have a deleterious or likely patho-
genic mutation, and 50% of those 
individuals (n=37) had undergone 
panel testing (versus SS, SG, or BRCA-
limited testing). Only one-third (32%, 
n=12) of the panel-tested individuals 
were found to have BRCA mutations, 
and one of those patients was found to 
have both a BRCA and CHEK2 muta-
tion. Twenty-three individuals were 
diagnosed with non-BRCA muta-
tions that would have been missed by 
BRCA testing alone, representing 31% 
of those testing positive for a muta-
tion (n=75) and 62% of those testing 
positive who had undergone panel 
testing (n=37). True negatives, those 
testing negative for known familial 
mutation, encompassed 8% (n=35) of 
those tested. A variant of uncertain 
significant (VUS) was found in 28% 
(n=121) of those tested, and both a 
VUS and deleterious mutation were 
found in 2% (n=8) of those tested. 
One-quarter (26%, n=109) of patients 
who underwent genetic testing had a 
change in management; all those who 
were found to have a mutation, except 
for one, had an increase in surveil-
lance and/or prophylactic measures 
(Table), while all true negatives had a 
decrease from what would have been 
planned had testing not occurred. All 
individuals with a VUS or a mutation 
in a moderate penetrance gene were 
encouraged to participate in a pro-
spective registry.
CONCLUSION: Panel testing for 
hereditary cancer syndromes can 
provide important information for 
guideline-driven clinical manage-
ment. Participation in prospective 
registries is essential for further 
development of clinical guidelines for 
individuals with variants of uncertain 
significance.
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FIGURE: A Typical 2-D Snapshot of the 3-D Rendering from a CT Scan 
Using Novapacs® with Abdominal Fat Selected from the Top of the Liver 
to the Pubic Symphysis 
On the left, normal coronal(A), sagittal(B), axial(C), and 3-D rendering(D) 
images are displayed. Coronal(E), sagittal(F), axial(G), and 3-D 
rendering(H) images are depicted.
Central adipose tissue is appreciated 
as a risk factor for cardio-metabolic 
disorders.1 The purpose of this study 
was to determine the efficacy of a new 
volumetric 3-D computerized tomog-
raphy (CT) software in determining 
mass and adipose tissue of human 
subjects compared to currently 
accepted methods of measuring 
adipose tissue, including the gold 
standard, hydrostatic weighing (HW, 
also called underwater weighing), and 
the recently innovated air displace-
ment plethysmography (ADP, also 
called BOD POD).2 We implemented 
this software on 1,225 patients to 
determine the predicting power that 
central abdominal adipose tissue 
would have on significant cardio-
metabolic diseases, namely hyperten-
sion, heart disease, high cholesterol, 
and diabetes.
Using NovaPACS® software, 
we implemented two commonly 
accepted algorithms of converting 
CT Hounsfield numbers to tissue 
densities, namely the Schneider 
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method and the Beam method.3 
Twenty volunteer subjects (14 men, 
six women) received head-to-toe CT 
scans and height and weight measure-
ments. HW and ADP were obtained 
from 17 and 12 subjects, respectively. 
When comparing ADP to CT data 
using the Schneider method and 
Beam method for total mass, corre-
lations were r = 0.9806 and 0.9804, 
respectively. Paired t-tests indicated 
there were no statistically signifi-
cant biases. Additionally, observed 
average differences in percent body 
fat between ADP and the Schneider 
method and the Beam method were 
0.38% and 0.77%, respectively. 4 
In other words, in a 200-pound 
individual, the Schneider method 
predicted the amount of body fat 
to be within .76 pounds of ADP 
measurements.
Using this newly innovated CT 
software, full body (i.e. neck to 
thighs) CT scans were obtained 
from 1,225 female (518) and male (707) 
subjects, aged 18-88. Percent central 
body fat (%cBF) was determined 
by quantifying the adipose tissue 
volume from the dome of the liver 
to the pubic symphysis (Figure). 
Calcium score was determined from 
the calcium content of coronary 
arteries. Relationships between 
%cBF, body mass index (BMI), and 
several cardio-metabolic disorders 
were assessed controlling for age, sex, 
and race. Higher %cBF was signifi-
cantly greater for those with Type 2 
diabetes and hypertension, but not 
stroke or hypercholesterolemia. 
BMI and %cBF correlated roughly 
equally with diabetes and hyperten-
sion. Calcium scoring significantly 
correlated with all measurements 
of cardiovascular health, including 
hypertension, hypercholesterolemia, 
and heart disease (Table).5
CT is not likely to be a screening 
tool for %cBF. However, millions of 
CT scans are performed on high-risk 
patients each year for other reasons. 
These patients can benefit from the 
additional information obtained 
by a quantitative, spatial analysis of 
adipose tissue within their body cor-
related to key cardio-metabolic dis-
eases. Providing this information to 
high-risk patients may provide valu-
able feedback for behavioral change. 
Furthermore, CT volume quantifica-
tion provides an essential foundation 
for more accurate stratification of 
risk based on the location of fat and 
could play a role in developing sur-
gical techniques to remove visceral 
abdominal fat. The application of 
these CT algorithms has utility in 
further research to accurately stratify 
risk factors with peri-organ, visceral, 
and subcutaneous types of adipose 
tissue and has the potential for sig-
nificant clinical application.
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TABLE: Body Mass Index, Percent Central Body Fat, and Calcium Scores According to Selected Variables 
Taken from 1,225 Patients
*Adjusting for age, sex, and race. †From the F statistic based on type III sums of squares. Fifteen different models are represented in the table.
BMI %cBF Calcium Score
Slope 
estimate* 
Standard 
error* P-value† 
Slope 
estimate* 
Standard 
error* P-value† 
Slope 
estimate* 
Standard 
error* P-value†
Hypertension 2.14 0.36 <0.0001 3.06 0.64 <0.0001 −118.9 30.73 0.0001
Heart disease −0.21 0.81 0.7911 −0.32 1.43 0.8232 −444.1 68.34 < 0.0001
High cholesterol −0.32 0.35 0.3600 −0.61 0.63 0.3342 −115.3 29.93 0.0001
Diabetes 3.73 0.53 <0.0001 4.09 0.95 <0.0001 −57.0 45.26 0.2085
Former smoker 0.8 0.36 0.0250 1.47 0.64 0.0215 −72.2 30.34 0.0175
22 Fusion ♦ 2017
CASE REPORT: A 22-year-old previ-
ously healthy myopic white female 
presented with unilateral pain-
less central scotoma, followed by 
increasing temporal visual deficit. 
She denied photopsia, dyschroma-
topsia, f loaters, or recent f lu-like 
symptoms. Corrected visual acuity 
was 20/100 improving to 20/70 with 
pinhole in the right eye and 20/20 in 
the left. Confrontation visual fields 
revealed a central and inferotem-
poral visual field defect. Amsler grid 
testing showed central and paracen-
tral relative scotomas and an enlarged 
blind spot. Intraocular pressure, slit 
lamp exam, motility were normal, 
with a relative afferent pupillary 
defect noted in the right eye. Past 
ocular history was significant for 
high myopia in both eyes and cho-
rioretinal scars in the right eye from 
what was presumed ocular histoplas-
mosis (POHS). 
The fundus exam was significant 
for chorioretinal scars (Figure 1). One 
scar is in the papillomacular bundle, 
and a concentrically oriented group 
of scars is temporal to the macula. 
The macula had an orange coloration 
with a granular appearance. A few 
faint lighter colored spots were found 
in the nasal midperiphery, seen in 
Figure 3. The nasal margin of the 
optic nerve was slightly indistinct. 
There was a soft, yellowish spot 
temporal to the macula. 
Spectralis optical coherence 
tomography (OCT) revealed attenu-
ation of the ellipsoid zone seen in 
Figure 2. Fluorescein angiography 
did not show significant abnormality 
other than the chorioretinal scars, 
and indocyanine green showed 
hypof luorescent spots concentri-
cally around the optic nerve, and 
in the nasal midperiphery seen in 
Figure  3. Fundus autofluorescence 
showed hyperautofluorescent lesions 
temporal to the macula and nasal to 
the optic nerve (Figure 4). 
T he d i f ferent i a l  d i a g nosi s 
i ncluded M EW DS, pu nct uate 
inner choroidopathy (PIC), mul-
tifocal choroiditis and panuveitis, 
and AZOOR (acute zonal occult 
outer retinopathy). A diagnosis of 
MEWDS and concurrent MFC was 
made, given the fundus findings and 
diagnostic tests.
DISCUSSION: We present what is 
believed to be the first case of an 
atypical MEWDS with a paucity of 
white spots, and concurrent scars 
consistent with MFC.  Although 
the patient did not present with 
multifocal grey-white lesions char-
acteristic of MEWDS, she did have 
the characteristic orange-yellow 
fovea with granularity seen on fundus 
examination along with attenua-
tion of the ellipsoid zone on OCT. 
The peripapillary hypoflourescence 
on ICG and hypoautof lourescent 
around the optic nerve on fundus 
autoflourescence are consistent with a 
diagnosis of MEWDS and follow the 
clinical characteristics of acute onset 
central loss of vision and an enlarged 
blind spot.1 The previous diagnosis of 
POHS seemed unlikely due to lack 
of characteristic peripapillary scar-
ring. The scar located in the papil-
lomacular bundle could be the result 
of either PIC or MFC; however, the 
concentrically oriented group of scars 
temporal to the macula is indicative of 
MFC since PIC primarily has scars in 
the papillomacular bundle.2,3  
The consecutive occurrence of 
MEWDS and MFC has been docu-
mented in the literature, and there 
has also been one case documenting 
typical MEWDS and MFC concur-
rently occurring; however, no clear 
We believe the advent of retinal imaging technology such as SD-OCT 
and ICG has increased the diagnostic efficacy of MEWDS, and FUNDUS 
photography has improved the diagnostic efficacy of MFC, which 
allowed the diagnosis of atypical MEWDS with concurrent MFC that has 
not been described previously. 
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A Case of Atypical Multiple Evanescent 
White Dot Syndrome and Multifocal 
Choroiditis in a 22-Year-Old Woman
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FIGURE: 1. Fundoscopy of the right eye revealing chorioretinal scars. 2 OCT demonstrating attenuation of 
the ellipsoid zone. 3. Indocyanine green revealing hypofluorescent spots. 4. Autofluorescence demonstrating 
hyperautoflurescent lesions.  
link between the two syndromes has 
been discovered.4,5  There have been 
numerous theories proposed encom-
passing a pathogen or predisposition 
to a pathogenic mechanism. There 
has also been proposed sensitization 
to autoantigens in these patients.4  
We believe the advent of retinal 
imaging technology such as SD-OCT 
and ICG has increased the diagnostic 
efficacy of MEWDS, and FUNDUS 
photography has improved the 
diagnostic efficacy of MFC, which 
allowed the diagnosis of atypical 
MEWDS with concurrent MFC that 
has not been described previously. 
REFERENCES
1. Abu-Yaghi NE, Hartono SP, Hodge DO, 
Pulido JS, Bakri SJ. White dot syndromes: A 
20-year study of incidence, clinical features, 
and outcomes. Ocul Immunol Inf lamm. 
2011;19(6):426-430. 
2. Parnell JR, Jampol LM, Yannuzzi LA, Gass 
JD, Tittl MK. Differentiation between 
presumed ocular histoplasmosis syndrome 
and multifocal choroiditis with panuveitis 
based on morphology of photographed 
fundus lesions and fluorescein angiography. 
Arch Opthalmol. 2001;119(2):208-212.
3. Kedhar SR, Thorne JE, Wittenberg S, 
Dunn JP, Jabs, DA. Multifocal choroi-
ditis with panuveitis and punctate inner 
choroidopathy: comparison of clinical 
characteristics at presentation. Retina. 
2007;27(9):1174-1179. 
4. Shelsta HN, Rao RR, Bhatt JK, Jampol LM. 
Atypical presentations of multiple evanes-
cent white dot syndrome without white 
dots: a case series. Retina. 2011;31(5):973-6. 
5. Schall S, Schiff WM, Kaplan HJ, Tezel 
TH. Simultaneous appearance of multiple 
evanescent white dot syndrome and multi-
focal choroiditis indicate a common causal 
relationship. Ocul Immunol Inf lamm. 
2009;17(5):325-327.
24 Fusion ♦ 2017
Epidermoid cysts account for 1-2 
percent of all brain tumors and 
are most commonly found in the 
cerebellopontine angle and para-
sellar cisterns.1 The slow growth of 
these tumors often results in them 
remaining asymptomatic until their 
size is large enough to compress 
surrounding structures, such as the 
pituitary stalk or optic chiasm.2 
These cysts are believed to develop 
during the embr yonal period of 
development, more specifically the 
third to fifth weeks of gestation, with 
displacement of dorsal ectodermal 
cells normally residing in the mid-
line.3 The incomplete separation of 
the neural and epidermal ectoderm 
allows for epiblast inclusion in the 
neural tube, which typically closes 
during this gestational period.3 Most 
often, these tumors are diagnosed in 
adults aged 20–40 years old, with inci-
dence peaking in the fourth decade 
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of life.3 A trans-sphenoidal approach 
for the removal of these tumors has 
been shown to reduce morbidity and 
mortality in these patients due to 
the better visualization of the neo-
plasm and surrounding anatomy and 
minimal (if any) brain retraction.2 
Tumors and cysts of the pituitary 
stalk and hypothalamic region vary 
in presentation depending on their 
location, progression, and extension 
into the surrounding anatomy, in 
addition to the age and comorbidities 
of the patient; all of these factors must 
be addressed prior to surgery.4 
Here, we present a rare case of an 
epidermoid cyst located in the supra-
sellar region, specifically originating 
from the infundibulum (Figure 1 
and  2). Only one additional case 
with an epidermoid cyst originating 
within the pituitary stalk has been 
previously reported in the literature. 
The patient in this case presented 
with headaches, diplopia, and blurred 
vision without any endocrinopathy. 
The patient’s pre-operative evalua-
tion was significant for pseudotumor 
cerebri, hyponatremia, obesity, and 
a history of smoking; post-operative 
course was significant for neurogenic 
diabetes insipidus. The only other 
reported case of an epidermoid cyst 
occurring within the infundibulum 
involved a young female patient who 
presented with a two-year history 
of significant endocrine symptoms, 
including amenorrhea, galactorrhea, 
polyuria, and polydipsia.3 This patient 
also reported visual symptoms and 
a headache, as seen in our patient. 
Similarities between the two cases 
include gender, tumor type, and 
anatomical location; however, our 
patient was nearly 10 years senior 
and reported a more acute time 
course of one to two months. Both 
patients received subtotal resection 
of the tumor given its adherence 
to the stalk and close proximity to 
the optic chiasm. On pathological 
examination, both cysts contained 
keratin debris; however, our patient 
had a small region of calcification, 
suggestive of a Rathke cleft remnant.2 
While both patients fall into the age 
range for these lesions, 20–60 years 
of age, neither fits the peak incidence 
of the fourth decade of life.5 The 
FIGURE 1: Preoperative MRI with 
Contrast (Coronal View)
FIGURE 2: Postoperative MRI with 
Contrast (Coronal View) 
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similarities and differences between 
these cases highlight the variety of 
symptoms and clinical presentations 
of tumors residing within this region 
of the brain and the close attention to 
detail required in diagnosis.
As seen in our patient, tumors 
involving the pituitary stalk are chal-
lenging, given the high risk for post-
operative endocrinopathy and man-
agement of surrounding structures, 
including the hypothalamus, optic 
chiasm, and vessels within the cav-
ernous sinus. While other cases have 
presented with lesions intruding into 
the sellar region, epidermoid growth 
within the stalk itself is rare, and 
our patient is an excellent example 
of the neurosurgical management of 
an epidermoid cyst residing in this 
specific location.
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FIGURE 1: Geographic Distribution of Referring Centers (blue circles 
represent level I trauma facilities) 
Level 1 trauma centers are required 
to provide hand and microsurgery 
capability at all times.1 To better 
understand distant referrals and 
indirectly study triage patters in our 
region, we examined patient transfers 
for upper extremity amputation to 
our level 1 trauma center. We hypoth-
esize that patients are transferred to 
our academic, tertiary care center 
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despite the availability of closer, 
American College of Surgeons (ACS)-
designated level 1 trauma centers.2
Records were reviewed from 2010 
to 2015 to evaluate patients trans-
ferred to our level 1 institution for 
upper extremity amputation. Patients 
were referred from six states to our 
institution over this time period 
(Figure 1). We measured the straight-
line distance from each patient's 
transferring facility to our facility 
Patients Transferred for Upper Extremity Amputation: 
Participation of Regional Trauma Centers
 Continued on p. 26
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FIGURE 2: Distance of transport from transferring facility to either the 
nearest level I trauma center, or our facility as more distant level I trauma 
center (FIG. 2-A); trauma designation of transferring facility (n= 27)  
(FIG. 2-B).
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and compared this distance to the 
straight-line distances from the zip 
code of the transferring facility to the 
zip code of each level 1 trauma center.
We had data for 250 transferred 
patients (91% male, 9% female). For 
110 patients, our hospital was the 
nearest level 1 trauma center; how-
ever, for the remaining 140 patients, 
other level 1 trauma facilities were 
located closer to the referring hos-
pital. Among these 140 patients, the 
mean distance of the referring facility 
to the nearest level 1 trauma center 
was significantly different from the 
mean distance of the referring facility 
to our facility (Figure 1A). An average 
of four level 1 trauma centers were 
bypassed before patients arrived at 
our center. Medicaid and “self-pay” 
patients were more likely to be trans-
ferred to our facility. 
Twenty-seven of 140 patients 
(19%) were transferred from a facility 
with a trauma designation; the other 
81% were transferred from a facility 
without a trauma designation. Out of 
these 27 patients transferred from a 
facility with a trauma designation, 18 
patients (67%) were transferred from 
a level 1 trauma center. The remaining 
patients were transferred from a level 
2 trauma center (n= 4, 15%) or a level 3 
trauma center (n= 5, 18%) (Figure 1B). 
Bivariate analysis showed that 
insurance status was associated with 
more distant transfer. After control-
ling for possible confounders using 
multivariable logistic regression 
analysis, we found that patients with 
Medicaid (OR 6.7; 
CI 1.5 - 33; standard 
error (SE) 5.5; P= 
0.015) and patients 
w h o  w e r e  s e l f -
paying, i.e. “unin-
sured” (OR 3.3; CI 
1.2 - 10; SE 1.8; P= 
0.024), were more 
likely to be trans-
ferred to our facility 
as a more distant 
level 1 trauma center than patients 
who had private insurance
Fifty-six percent of patients trans-
ferred to our hospital for upper 
extremity amputation had a level 1 
trauma center closer to their injury. 
This study demonstrated that a 
substantial number of patients with 
upper extremity amputation are 
transferred to our academic, level 1 
institution despite the availability 
of closer level 1 trauma centers. This 
suggests that microsurgical expertise 
for replantation is unofficially rec-
ognized by referring facilities in 
surrounding states – even those with 
level 1 ACS accreditation. Our center 
has an interest in providing care 
for these complex patients and in 
providing quaternary microsurgical 
coverage for the region. Formal des-
ignation of regional microsurgical 
trauma centers may facilitate patient 
triage, expeditious referral and trans-
port, and ultimately improvement 
in outcomes for patients with upper 
extremity amputations.  
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This study demonstrated that a substantial 
number of patients with upper extremity ampu-
tation are transferred to our academic, level  1 
institution despite the availability of closer level 1 
trauma centers. 
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FIGURE: Adjusted AN count by quarter, for patients who ever vs. never 
had HS surgery. Error bars show 95% CI each quarter
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BACKGROUND: 
Hidradenitis suppurativa (HS) is a 
chronic, recurrent, inf lammatory 
disease of the apocrine sweat glands 
that affects approximately 1 – 4 percent 
of the population.1, 2 There is currently 
no known cure, and molecular drivers 
of HS are poorly understood. While 
traditional disease-modifying anti-
rheumatic drugs (DMARDS) have 
been largely ineffective, targeted 
biologic therapy, including TNF-α 
inhibitors, have been used with some 
success.3 Adjuvant biologic therapy 
after radical resection has been shown 
to reduce the risk of recurrence 
in HS. Unti l now, longitudina l 
investigations of clinical outcomes 
in HS patients undergoing surgical 
and biologic interventions have been 
largely retrospective.4,5 The purpose 
of this study is to investigate how 
interventions such as surgery and 
biologic treatment in HS impact 
disease activity scores.  
METHODS:
This research was conducted through 
the Wound Etiology and Healing 
(WE-HEAL) study. At the time of 
data-lock, 565 patients were enrolled 
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in the WE-HEAL study, and 69 
had HS. 
HS disease activity was assessed 
using Active Nodule count (AN 
count), Hurley Stage, and Hidradenitis 
Sa rtorius Score ( HSS). Patient 
variables included baseline disease 
activity scores, age, gender, race, 
ethnicity, smoking, disease duration, 
and baseline comorbidities. Analysis 
was performed using the SAS Mixed 
and GLM procedures for multivariate 
analysis (version 9.3, Cary, NC) with 
p<0.05 considered significant. 
RESULTS: PATIENT CHARACTERISTICS
The mean age of the HS subjects 
wa s 40. 4 yea rs (SD 13 .8),  72 .5 
percent were African American, 
and 65.2 percent were female. There 
were no significant differences in 
demographic characteristics in the 
patients who underwent surgery or 
biologic therapy (Table). As expected, 
patients with a higher baseline HSS 
score were more likely to have ever 
been exposed to biologics (p=0.021). 
RESPONSE TO THERAPY 
BASED ON HSS SCORE:
After adjusting for the effects of 
time-varying surgery, time-varying 
BMI, time-varying opioid dose, time-
varying pain score, baseline Hurley 
Response of Hidradenitis 
Suppurativa to Biologic Therapy
 Continued on p. 28
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TABLE: Baseline Demographics of HS patients Stratified by Surgery and Biologic Exposure
Variable Surgery Biologics
All Patients (n=69) Ever (n=33) Never (n=36) P Ever (n=27) Never (n=42) P
Age 40.4 (13.8) 38.6 (12.6) 42.0 (14.8) 0.32 39.1 (11.0) 41.2 (15.4) 0.54
Race AA 50 (72.5%) 23 (69.7%) 27 (75.0%) 0.55 20 (74.1%) 30 (71.4%) 0.40
Caucasian 18 (26.1%) 9 (27.3%) 9 (25.0%) 6 (22.2%) 12 (28.6%)
Asian 1 (1.5%) 1 (2.0%) 0 1 (3.7%) 0 (04%)
Female Gender 45 (65.2%) 19 (57.6%) 26 (72.2%) 0.20 16 (59.3%) 29 (69.1%) 0.40
Smoker Current 16 (23.2%) 11 (33.3%) 5 (13.9%) 0.13 6 (22.2%) 10 (23.8%) 0.57
Former 17 (24.6%) 5 (18.2%) 11 (30.6%) 5 (18.5%) 12 (28.6%)
Never 36 (52.2%) 16 (48.5%) 20 (55.6%) 16 (59.3%) 20 (47.6%)
Disease Duration 9.3 (11.7%) 8.1 (9.1%) 10.7 (14.3%) 0.50 9.0 (7.0%) 9.5 (14.2%) 0.12
Baseline HSS 61.3 (45.2%) 65.6 (41.0%) 57.1 (49.2%) 0.45 77.0 (47.2%) 50.8 (41.1%) 0.021
Stage, smoking, and hypertension, 
patient-quarters with biologics 
present had a mean HSS 12.0 points 
lower than patient-quarters without 
biologics (p=0.009). 
AN COUNT RESPONSE
In the random effects mixed model, 
significant predictors of improvement 
in the AN count included having HS 
surgery (p=0.0016), disease activity 
at baseline (Hurley stage 2 (p=0.034) 
or 3 (p<0.0001)), having biologics 
prescribed (time varying; p=0.001), 
time (quarter; p<0.0001), and the 
surgery x time interaction (p=0.0031). 
A N count dropped more for 
patients undergoing surgery than not 
undergoing surgery (Figure). After 
adjusting for time-varying surgery 
and other covariates, biologic use 
was associated with a drop of 0.6 AN 
units compared to no biologic use 
(p=0.0029).
DISCUSSION: 
T he cohor t  of  H S 
patients followed in 
the WE-HEAL study 
is representative of the 
population affected in 
the United States with 
a higher prevalence of 
women and African 
Americans.2 In this 
s t u d y,  w e  s h o w e d 
t h a t  t r e a t m e n t 
with biologic agents significantly 
decreases disease activity scores, 
which is consistent with other clinical 
studies demonstrating response of 
moderate to severe HS to TNF-α 
inhibition.3 We demonstrated a 
similar response in our predominantly 
African American population and 
demonstrated that treatment with 
biologic agents, in combination 
with surgery, was associated with 
significant improvement in disease 
activity scores in this population. 
The primar y l imitation of this 
study is small sample size. However, 
recruitment of patients with HS into 
the WE-HEAL study is ongoing. 
With this data set, we hope to be able 
to further investigate the interplay of 
biologic therapy and surgery in HS 
management.
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In this study, we showed that treatment with 
biologic agents significantly decreases disease 
activity scores, which is consistent with other 
clinical studies demonstrating response of 
moderate to severe HS to TNF-α inhibition.3
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In the United States, urolithiasis 
affects approximately 1 in 11 people, 
and there is evidence that the preva-
lence is increasing. A recent treat-
ment strategy for urolithiasis involves 
using Medical Expulsive Therapy 
(MET) to increase the likelihood 
of spontaneous passage of ureteral 
stones. The two leading drug classes 
for MET are alpha-1-andrenergic 
receptor blockers and calcium-
channel blockers. Tamsulosin, an 
alpha-1-adrenocepter blocker, is 
thought to induce spontaneous 
stone passage by relaxing ureteral 
smooth muscle tone in the pros-
tate and bladder neck. In principle, 
tamsulosin binds to alpha-1a-recep-
tors and alpha-1d-receptors on the 
ureter smooth muscle, causing dila-
tion of the ureteral lumen, thereby 
decreasing peripheral resistance from 
the ureteral wall and subsequently 
increasing urinary flow.1 However, 
tamsulosin has not been proven 
effective for increasing ureteral stone 
passage and is not approved by the 
U.S. Food and Drug Administration 
for this indication as it was originally 
designed to treat the symptoms of 
benign prostatic hyperplasia. There 
is a relative paucity of data on the 
efficacy of tamsulosin for urolithiasis, 
and of the published results, there 
are conf licting conclusions from 
the data. Due to the acute nature of 
symptoms from urolithiasis, emer-
gency medicine physicians are often 
the first to diagnose and treat this 
condition. This has led to tamsulosin 
being frequently prescribed 
from the emergency depart-
ment ( ED) for off-label 
use without the support of 
high-quality evidence. If 
tamsulosin is proven effec-
tive, its use in the treat-
ment of urolithiasis could 
offer important advantages. 
The number of procedures, 
length of hospital stay, and 
hea lth ca re costs after 
the initial ED visit could 
potentia l ly be reduced. 
Tamsulosin may also increase patient 
satisfaction by reducing invasive 
treatment and decreasing time to 
stone passage. We conducted a lit-
erature review that focuses on the 
efficacy of tamsulosin. A few data 
insights are highlighted below.
A meta-analysis of 20 randomized 
control trials that had a combined 
1,593 patients found that the expul-
sion rate in the tamsulosin group was 
significantly higher than that of the 
control group for both distal ureteral 
stones (P < 0.00001) and proximal 
ureteral stones (P = 0.02).2 This 
meta-analysis found that tamsulosin 
decreased average time to expulsion 
by 3.36 days for proximal stones and 
3.66 days for distal stones compared 
Rahul 
Nadendla, MSII 
ADVISORS:  
Ali Pourmand, M.D., 
M.P.H.;1 Maryann 
Mazer-Amirshahi, 
M.D., Pharm.D.;2 
Francis O’Connell, 
M.D.1 
 
1Department of Emergency Medicine, 
The George Washington University,  
School of Medicine and Health Science 
2Department of Emergency Medicine, 
MedStar Washington Hospital Center, 
Washington, D.C.
to the control group.2 However, one 
randomized control trial with 1,136 
patients has shown that tamsulosin 
is not more effective than a placebo 
at increasing the likelihood of stone 
expulsion.3 This study had 81% 
spontaneous stone passage in the 
tamsulosin group compared to 80% 
spontaneous stone passage in the 
placebo group.3 A meta-analysis with 
a combined 1,283 patients comparing 
tamsulosin use to placebo in the ED 
showed that tamsulosin had a higher 
rate of stone expulsion (P <  0.001) 
and a decreased stone expulsion time 
(P = 0.02).4 In addition, the study 
found decreased need for analgesic 
therapy, hospitalization, and sur-
gery following the initial ED visit.4 
However, a different study, a prospec-
tive trial of 100 ED patients who were 
randomized to either 0.4 mg daily of 
tamsulosin or placebo for seven days, 
showed that there was no difference 
in proportion of stone passage after 
the seven days between tamsulosin 
and placebo.5
While tamsulosin has shown 
potential as an effective treatment 
While tamsulosin has shown potential as an 
effective treatment option for urolithiasis, 
there is still need for additional investiga-
tion on the efficacy of tamsulosin in the 
acute setting in order to be justified for pre-
scription from the emergency department.
 Continued on p. 30
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FIGURE: Comparison of Continua of Care for HCV Monoinfected and 
HCV/HIV Coinfected Individuals during Two Treatment Eras
option for urolithiasis, there is still 
need for additional investigation 
on the efficacy of tamsulosin in the 
acute setting in order to be justified 
for prescription from the emergency 
department.
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Re cent  a d v a ncem ent s  i n  t he 
treatment of the Hepatitis C virus 
( HCV ) have resulted in a shift 
from pegylated interferon-based 
regimens to the use of direct acting 
agents (DAAs).  Untreated HCV 
can evolve into cirrhosis and liver 
decompensation, both of which are 
three times more common in HCV/
HIV coinfected individuals than 
HCV monoinfected individuals.1 The 
goal of HCV treatment is to achieve 
sustained virologic response (SVR), 
which is associated with decreased 
rates of end-stage l iver disease 
(ESLD), hepatocellular carcinoma 
(HCC), and death.2 Previously, SVR 
was assessed 24 weeks following the 
end of treatment (SVR24); however, 
an undetectable HCV viral load 12 
weeks following treatment (SVR12) is 
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now sufficient for defining treatment 
success.3 
Prior to the development of 
DAAs, pegylated interferon-based 
regimens would result in 41 percent 
of monoinfected patients and 27 per-
cent of coinfected patients achieving 
SVR.1 DAAs have resulted in SVR 
in approximately 90 percent of all 
patients.3 While safety, tolerance, 
and efficacy of DAAs are similar 
for both HCV monoinfection and 
HCV/HIV coinfection, drug interac-
tions with coinfected patients’ HIV 
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antiretroviral agents (ARVs) must be 
considered prior to initiation of HCV 
treatment.4
The Washington DC Veterans 
Affairs Medical Center (DC-VAMC) 
provides comprehensive care for 
veterans in the greater metropolitan 
area of the District of Columbia. 
The Infectious Disease Clinic at the 
DC-VAMC offers HIV care under a 
multidisciplinary model comprised of 
physicians, nurse practitioners, psy-
chologists, social workers, and phar-
macists. From 2008-13, pegylated 
interferon-based regimens were used 
to treat HCV infection.  Beginning 
in 2014, DAAs became the preferred 
treatment. We describe the HCV 
Continuum of Care (CoC) at the 
DC-VAMC for both HCV monoin-
fected and HIV/HCV coinfected 
individuals treated between 2008 
and 2015. 
A retrospective review of the 
HCV Clinical Case Registry (HCV 
CCR) at the DC-VAMC was con-
ducted for the pegylated interferon 
treatment era (2008-13) and the DAA 
era (2014–15). The patients were ana-
lyzed based on a modified HCV CoC: 
HCV diagnosis, engaged in medical 
care, prescribed HCV medication, 
and achievement of a not detect-
able HCV viral load.  Depending on 
sample size, two-tailed Chi-square 
with Yate’s correction and two-tailed 
Fisher’s Exact Test were used to 
assess for differences between mono 
and coinfected patients. The tests 
were also used to assess for differ-
ences within the monoinfected and 
coinfected groups dependent upon 
treatment era.  
Based on the proportions of 
patients in the HCV CoC for both 
treatment eras seen in the Table 
and the Figure, more monoinfected 
patients achieved HCV suppres-
sion in the pegylated interferon era 
than coinfected patients (48.32% vs. 
18.18%, p= 0.007, Fisher’s). While 
a similar proportion of coinfected 
and monoinfected patients achieved 
suppression in the DAA era, more 
coinfected patients were treated 
(36.12% vs. 22.94%, p< 0.0001, Chi-
square). Compared to the pegylated 
interferon era, a greater propor-
tion of monoinfected patients were 
treated (22.93% vs. 6.00%, p< 0.0001, 
Fisher’s) and achieved HCV suppres-
sion (90.63% vs. 48.33%, p< 0.0001, 
Fisher’s) through the use of DAAs. 
Similarly, more HCV/HIV coin-
fected patients were treated (36% vs 
5%, p<0.0001, Fisher’s) and had HCV 
suppression (86% vs 19%, p<0.0001, 
 Continued on p. 32
TABLE: Comparison of Proportion of Patients Along HCV Continuum of Care
2008–13, Pegylated 
Interferon
All Patients HCV/HIV 
Coinfection
HCV Monoinfection P Value*
HCV Supression 134 (2.76%) 4 (18.18%) 130 (48.33%) 0.007 1*
2014–15, Direct  
Acting Agents
All Patients HCV/HIV 
Coinfection
HCV Monoinfection P ValueA
HCV Treatment 834 (23.86%) 108 (36.12%) 726 (22.94%) <0.0001 2*
HCV/HIV Coinfection All Patients 2008–13,  
Pegylated Interferon
2014–15, Direct 
Acting Agents
P ValueB
HCV Treatment 130 (18.36%) 22 (5.39%) 108 (36.0%) <0.0001 1*
HCV Supression 97 (13.70%) 4 (0.98%) 93 (31.00%) <0.0001 1*
HCV/HIV 
Monoinfection
All Patients 2008–13,  
Pegylated Interferon
2014–15, Direct 
Acting Agents
P ValueB
HCV Treatment 995 (13.01%) 269 (6.04%) 726 (22.72%) <0.0001 1*
HCV Supression 788 (10.30%) 130 (2.92%) 658 (20.59%) <0.0001 1*
A Comparison made between monoinfected and coinfected groups
B Comparision made between treatment eras
1 Two-tailed Fisher’s Exact Test
2 Two-tailed Chi-square with Yate’s Correction
* Significantly different proportion
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FIGURE 1: Magnetic resonance spectroscopy analysis of chemicals in the brain during symptomatic periods 
as compared to asymptomatic periods. () denotes an increase of the corresponding chemical in the brain 
compared to the patient’s baseline. () denotes a decrease of the corresponding chemical in the brain 
as compared to the patient’s baseline. (-) denotes no difference in the corresponding chemical between 
symptomatic and asymptomatic periods. 
Fisher’s) during the DAA era than in 
pegylated interferon.  
Greater proportions of both 
HCV monoinfected and HCV/HIV 
coinfected patients were treated 
and achieved HCV viral suppres-
sion during the DA A era at the 
DC-VAMC. HCV/HIV coinfected 
patients treated in the DAA era 
achieved similar suppression rates 
compared to monoinfected patients. 
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BACKGROUND: Urea cycle disorders 
are among the most common of the 
inborn errors of metabolism. These 
disorders affect up to 1/25,000 live 
births in the United States, and 
the number of children affected by 
partial defects may be much higher. 
Urea cycle disorders can lead to 
high rates of disability if not treated 
early. The urea cycle converts nitrog-
enous waste, a toxic byproduct of 
protein metabolism, into urea, a 
safe compound which is excreted in 
the urine. Children with urea cycle 
disorders are unable to fully metabo-
lize nitrogenous waste in the liver, 
resulting in high levels of ammonia 
in the blood. Hyperammonemia has 
well-known neurologic sequelae. 
However, the structural and chemical 
consequences of high ammonia in the 
brain of a developing child have not 
been well-defined. Furthermore, due 
to compartmentalization, ammonia 
Patient Thalamus
Peri-
insuar 
region
Basal 
ganglia
Globus 
pallidus
Frontal 
lobe
Temporal 
lobe
Parietal 
lobe
Occipital 
lobe
Corpus 
Callosum
Volume 
loss
Brain 
stem
1 — — — — + — — — —
2 — + + + + + + — + + +
3 — + + + + + + — — — +
4 — + + + + + + — — + —
5 — — — + + + + — — — —
6 — + + + + + + + — — +
7 — — + + — — — — — — —
8 — + + + + + + + — — +
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FIGURE 2: Table showing areas of the brain most affected in children with urea cycle disorders as evaluated 
by magnetic resonance imaging. (+) denotes that the area in question had structural change, while (—) denotes 
that the area in question showed no structural change.
Patient NAA Glutamine Glutamate Creatine Choline Myoinositol Lactate Lipid
1    —    
2    — —   
3    —    
4 — — — —  —  
5 — — — —  — — —
6 —      — —
7 — — — — — — — —
8 — — — — — — — —
levels in the blood do not correlate 
well with levels of ammonia in the 
brain. Additionally, patients who 
experience high brain ammonia 
levels are not always symptomatic. 
OBJECTIVE: To define with mag-
net ic  reson a nce spect roscopy 
(MRS) how the chemical levels of 
N-acetylaspartic acid, glutamine, 
glutamate, creatine, choline, myo-
inositol, lactate, and lipids vary from 
the norm in a child experiencing 
hyperammonemia. An additional 
objective is to evaluate the brain 
magnetic resonance images (MRI) of 
these same patients to identify parts 
of the brain most affected by high 
ammonia levels. 
METHODS: This was a retrospective 
study in which eight patients with var-
ious genetic defects in the urea cycle 
were identified. A neuroradiologist 
read the MRI and MRS data, and the 
data were analyzed for similarities. 
RESULTS: MRS data (Figure 1)
showed that brain levels of myo-
inositol are decreased in patients 
with hyperammonemia. Levels of 
lactate, glutamate, glutamine, and 
choline are increased. 
N-acetylaspartic 
acid may be either 
decreased or normal. 
Creati ne a nd l ipid 
levels remain normal. 
MRI data (Figure 2) 
showed that areas of 
the brain affected by 
high ammonia are the 
peri-insular region, the globus pal-
lidus, and the frontal, temporal, 
and parietal lobes. The thalamus, 
occipital lobe, corpus callosum, and 
brain stem were unaffected in these 
patients.
CONCLUSION: The findings in this 
small retrospective study indicate 
that there may be a distinct chemical 
footprint of changes that occur in 
the brain when ammonia levels are 
high. This suggests that MRS could 
be a better tool to evaluate the bio-
chemical consequences of high levels 
of ammonia in the brain rather than 
a blood ammonia level. Furthermore, 
MRI data suggest  there are distinct 
regions of the brain that are more 
sensitive to the effects of hyperam-
monemia than others. 
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[Results from this] retrospective study indicate 
that there may be a distinct chemical foot-
print of changes that occur in the brain when 
ammonia levels are high.
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Understanding the chronic effects of 
a microgravity environment on bone 
is essential, since humans are now 
considering new long-distance space-
flight missions. Prior to these mis-
sions, it is important to acknowledge 
that the negative effects of long-dura-
tion spaceflight on bone may increase 
the risk of musculoskeletal injuries.1 
As a result, management options for 
these types of injuries, particularly 
fractures, should be addressed. The 
objective of this study was to deter-
mine high-risk bone fracture areas 
after long-duration spaceflight, and 
identify management protocols for 
those fractures. 
A literature search was conducted 
for information on current fracture 
risk predictive models and sug-
gestions for treatment. It is well 
known that bone mineral density 
(BMD) decreases during long-dura-
tion spaceflight.1,2 This is likely the 
result of decreased load on bone in 
a microgravity environment, which 
leads to an uncoupling between 
bone resorption (increased) and bone 
remodeling (stable or decreased), 
also causing diminished bone frac-
ture healing.2 While the risk of 
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Fracture Risk in Spaceflight and  
Potential Treatment Options 
fracture in a microgravity environ-
ment is believed to be low, the poten-
tial risk for fracture increases upon 
re-entering a gravity environment 
(such as the Earth, the moon, or 
Mars).1,2 
The Bone Fracture Risk Model 
(BFxRM) is an algorithm developed 
to determine the probability of 
fracture at a particular skeletal site 
in a given loading scenario.2 As pre-
dicted by this model, there is greater 
fracture risk of the lumbar spine, 
femoral neck, and wrist, especially 
with increased mission duration and 
subsequent physical activity once 
re-introduced to a gravity environ-
ment.2 While there are many viable 
suggestions for mitigating bone 
fracture risk, there are limited proven 
management options. Exercise is 
part of a fundamental long-duration 
spacef light strateg y to mitigate 
BMD loss, and BMD improvement 
with exercise has been augmented 
by the introduction of the advanced 
resistance exercise device (ARED) 
on the International Space Station. 
Additionally, studies have shown 
that supplementation with bisphos-
phonates has an additive effect for 
preventing bone loss.1 
If a fracture were to occur, prom-
ising treatment options to improve 
bone fracture healing in space (in 
addition to standard management 
modalities such as splinting) include 
the use of low-intensity pulsed ultra-
sound, electromagnetic field therapy, 
and intermittent subcutaneous injec-
tions of parathyroid hormone.3, 4 
In the event of a complex fracture, 
surgical intervention with a universal 
external fixation device could be a 
viable option for management.5
In conclusion, the best strategy 
for reducing musculoskeletal inju-
ries for deep-space missions will be 
a combination of BMD loss reduc-
tion coupled with improvements in 
management protocols for potential 
fractures. 
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With passage of the Affordable 
Care Act (ACA) in 2010, 32 states 
— including Washington, D.C., and 
Maryland — expanded their Medicaid 
insurance coverage. Nineteen states, 
including Virginia, did not expand 
their coverage. Within the Medicaid 
expansion states, specific eligibility 
requirements vary.1 For example, 
non-elderly (under 65), non-disabled 
adults without dependent children 
are eligible for Medicaid in D.C. with 
annual incomes up to 210 percent of 
the Federal Poverty Level (FPL).2 In 
Maryland, these same patients are 
eligible at annual incomes up to 133 
percent of FPL (the ACA’s Medicaid 
Expansion minimum standard).2 In 
Virginia, these patients are not eli-
gible for Medicaid at all.2 
Trauma centers are required to 
treat all patients regardless of insur-
ance status, yet patients may have dif-
ferent hospital length of stay (LOS) 
depending on their access to care 
post-discharge. After controlling for 
injury severity, insured patients with 
increased access to post-discharge 
care, such as rehabilitation and home 
health services, have been found 
FIGURE: Adjusted Mean LOS by Insurance by State.
Adjusted for age, sex, ISS, AIS, and penetrating injury. Error bars show the 95% confidence 
interval. LOS = Length of Stay.  ISS = Injury Severity Score. AIS = Abbreviated Injury Score.
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to have a shorter LOS compared to 
uninsured patients.3,4 The purpose of 
this study is to identify if expanded 
Medicaid eligibility in D.C. and 
Maryland correlates with a shorter 
LOS for trauma patients, as it was 
shown to do with insured patients 
in general. A retrospective study of 
trauma registry patients admitted to 
the George Washington University 
Hospital, a Level 1 adult urban trauma 
center, during a 38-month period 
( Jan.  1, 2013, to March 6, 2016) 
was performed. Patients included 
those on non-commercial insurance, 
including Medicare and Medicaid, 
as well as those who were uninsured. 
Patients with commercial insur-
ance or whose payer information 
was not identified were excluded. 
Additionally, patients who were pro-
nounced dead on arrival or who died 
during their hospitalization were 
excluded. Primary outcome measures 
were comparison of type of insur-
ance and LOS by state of residence in 
Virginia, Maryland, and D.C.
During the study period, 4,883 
patients were admitted to the trauma 
service with 2,728 patients enrolled 
per our inclusion criteria. Medicaid 
patients from D.C. had a significantly 
shorter average LOS (2.64 days) than 
patients from Maryland (3.53 days, p = 
0.003) or Virginia (4.56 days, p = 0.02) 
(Figure). This difference persisted 
after controlling for Abbreviated 
Injury Score (AIS) for both head and 
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Clavicle fractures play a significant 
role in high-profile athletes’ per-
formance. Large-scale studies have 
reported that clavicle fractures 
make up 30 percent of all fractures in 
athletes and are associated with the 
third longest timeline for return to 
play among sports-related fractures.1,2 
While studies have evaluated the 
duration of return to play, impact of 
surgical versus nonsurgical manage-
ment, and re-injury rates, there is a 
lack of studies assessing the long-
term impact on athlete performance 
after returning from this injury.3,4,5
Our study aimed to define the 
time to return to play following 
clavicle injuries in the National 
Football League (NFL) and to esti-
mate the quantitative effect on ath-
letic performance.
Data on NFL players who sus-
tained a clavicle fracture were col-
lected from 2000 to 2015. Outcomes 
data included time to return to play, 
yearly total yards and touchdowns 
for offensive players, and yearly total 
tackles, sacks, and interceptions for 
defensive players. Using previously 
accepted methodology, offensive 
power rating (OPR = [total yards/10] + 
[total touchdowns x 6]) and defensive 
power rating (DPR = total tackles + 
[total sacks x 2] + [total interceptions 
x 2]) were calculated for the injury 
season and one season before and 
after the injury season. Offensive and 
defensive control groups consisted of 
all players who completed the 2013 
NFL season without an identified 
clavicle injury.
The study group was comprised 
of 16 players who sustained a clavicle 
injury, including 14 offensive, two 
defensive, and one special teams 
players. All players returned to the 
NFL following injur y. Athletes 
returned to competition at a median 
of 2.6 months following injury and 
missed a median of seven games. 
Analysis of pre- and post-injury ath-
letic performance revealed no statis-
tically significant change after return 
to sport. There was a trend toward 
lower ratings by position in quarter-
backs, running backs, wide receivers, 
and offensive players overall, but this 
reached no statistical significance.
Following clavicle fracture, all 
players were able to return to play 
in the NFL. While there were some 
downward trends in offensive power 
rating post-injury, there was no sig-
nificant difference in power rating 
before and after injury.
pelvis, Injury Severity Score (ISS), 
gender, age, and penetrating mecha-
nism of injury in our multivariate 
linear regression model.
The D.C. and Maryland, states 
that participated in Medicaid expan-
sion, are associated with shorter 
hospital LOS for trauma patients 
than the non-expansion state of 
Virginia. However, as the result of 
the differing Medicaid coverage 
eligibility requirements in D.C. and 
Maryland, discrepancy also exists in 
LOS between these states. Expanded 
Medicaid coverage in D.C., which 
includes undocumented immigrants 
and individuals at higher federal 
poverty income thresholds, may 
result in financial savings opportu-
nities for trauma patients following 
injury. It is expected that Medicaid 
expansion is associated with shorter 
hospital LOS for trauma patients due 
to increased access to rehabilitation 
facilities and home health services. 
However, future work investigating 
the discharge destination of Medicaid 
patients under the ACA is needed. 
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FIGURE: Number of Cases Where Participants Accurately Categorized 
the Pathology as Either A Dermatomycosis or Not: Organized in Percent 
Ranges
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Dermatophyte infections involving 
the skin, hair, or nails affect an esti-
mated 25 percent of the world’s popu-
lation1 and accounted for 51 million 
outpatient visits over a 10-year period 
(1995-2004) in the United States 
alone.2 Dermatomycosis is routinely 
managed by dermatologists, though 
given the diversity of clinical presen-
tations, is sometimes misdiagnosed, 
which can result in inappropriate 
therapy, worsening of symptoms, and 
even result in additional skin and soft 
tissue infections.3
An interactive survey of board-
ce r t i f ie d  d e r m a tol o g i st s  w a s 
conducted at the 2016 Orlando 
Dermatology Aesthetic & Clinical 
Conference, during a seminar on 
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superficial mycotic infections. The 
structure of the sur vey entailed 
reviewing a presentation of a clinical 
image followed by responding to 
a simple yes or no question: is this 
a fungal infection? Data was gath-
ered anonymously via an audience 
response system and data tabulated 
using Microsoft Excel.
The raw data of the survey is pre-
sented in the Table. In all, 13 cases 
were presented, and the results are 
summarized in the Figure. Although 
the majority of the cases (8/13) were 
appropriately categorized by 50+% 
of the audience, this percentage 
decreased as accuracy of categoriza-
tion increased. For example, in only 
4 of the 13 cases did audience mem-
bers accurately categorize the cases 
> 75% accuracy. Moreover, there was 
only one case for which 90%+ of the 
audience appropriately categorized 
the case.
The study limitations included 
a lack of a measureable response 
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“Fungus Amungus” — A Common Disease State That 
Is Commonly Missed: A Survey Based Study
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TABLE: Participant Responses to Clinical Images
n (%)
Case Diagnosis Yes No
1 Secondary syphilis 16 (94.1 1 (5.9)
2 Tinea corporis 7 (46.7) 8 (53.3) 
3 Erosio interdigitalis blaastomyceticia 12 (70.6) 5 (29.4)
4 Tinea corporis 10 (52.6) 9 (47.4)
5 Tinea faciei 10 (58.8) 7 (41.2)
6 Pityriasis rosea 13 (76.5) 4 (23.5)
7 Tinea corporis 26 (86.7) 4 (13.3)
8 Majocchi’s granuloma 3 (13.0) 20 (87.0)
9 Tinea versicolor 18 (72.0) 7 (28.0)
10 Tinea pedis 22 (78.6) 7 (28.0)
11 Erythema annulare centrifugum 10 (33.3) 20 (66.7)
12
Woringer-Kolopp disease (Pagetoid 
Reticulosis)
12 (46.2) 14 (53.8)
13 Gram negative toe web infection 2 (6.1) 31 (93.9)
rate and a small sample size, which 
prevent significant conclusions from 
being made. However, the results 
do emphasize the protean clinical 
nature of cutaneous dermatomy-
coses and the ease with which one 
may miss the correct diagnosis. 
Secondary syphilis, annular psoriasis, 
and pityriasis rosea are among just a 
few inflammatory skin diseases that 
can mimic dermatophyte infections 
as illustrated herein. As such, these 
data underscore the importance of 
continued medical education on 
dermatophyte infections as well as 
proper education and training on 
bedside diagnostic techniques, such 
as potassium hydroxide, during resi-
dency and beyond.
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Hidradenitis suppurativa (HS) is a 
chronic, recurrent, inf lammatory 
disease of apocrine glands. The 
d isea se a f fects approx i m ately 
1  percent of the population, and 
there is currently no known cure. 
The immune mechanisms of HS 
are poorly understood. There is an 
unmet need to elucidate molecular 
drivers of HS in order to develop 
novel treatments and improve clinical 
outcomes for patients. Keratinocytes 
are cells found in the basal layer 
of the stratified epithelium that 
comprises the epidermis. Defective 
keratinocyte function is thought to 
play an important role in HS and is 
considered to be critical in disease 
prognosis and pathogenesis.1,2 The 
purpose of this study was to compare 
keratinocyte function in HS, chronic 
wound (CW), and normal (N) skin 
samples.
Scratch assays are an established 
method for investigating cellular 
function in vitro.3,4 Human epidermal 
keratinocy tes were cultured to 
FIGURE 1A: Keratinocytes from normal skin samples demonstrate 
significantly higher rates of scratch closure than those from chronic 
wounds or HS skin. Representative images from keratinocyte scratch 
migration assay showing chronic wound samples have delayed closure 
compared to normal. 
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Differences between Hidradenitis Suppurativa, 
Chronic Wounds, and Normal Keratinocytes in an  
In-Vitro Wound Closure Model
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FIGURE1B: The graph shows the percentage of scratch re-
epithelialization at different time points. Results are expressed as the 
mean ± SEM. Closure was significantly less in cultured keratinocytes 
from chronic wound specimens than from normal keratinocytes at all 
time points measured (* P<0.05 between normal keratinocytes and 
chronic wound keratinocytes at 24, 48, 72, and 96 hours). Significant 
difference was only seen between normal and hidradenitis keratinocytes 
at the 96 hour time point (~ P<0.05).
reach 80 percent conf luence and 
then a scratch was made using 
1  ml sterile tip of about 100um in 
diameter. Individual cultures were 
photographed at 0, 24, 48, 72, and 96 
hours after scratch using an inverted 
phase contrast microscope. Wound 
closure was determined as percentage 
decrease in total scratch surface area 
over time. 
Viable cells at 96 hours after the 
scratch in each group were determined 
by fluorescence microscope utilizing 
a live/dead vital dye staining method. 
Apoptosis was assessed by f low 
cytometry for each group at 96-hour 
time-point after initial scratch using 
a FITC-annexinV-Propidium Iodide 
(PI) method5 where apoptotic cells 
stains annexinV positive and necrotic 
cells are double positive for annexinV 
and PI. Multiplex cytokine analysis 
was used to measure cytokines and 
growth factors from cell culture 
supernatant collected at 0, 24, 48, 72, 
and 96 hours after scratch. 
S cr atch c los u re  r ates  were 
significantly slower in HS and CW 
compared to normal (Figure 1A). 
Percent closure was significantly less 
in chronic wound keratinocytes than 
in normal keratinocytes at all time 
points measured (Figure 1B), whereas 
in the HS keratinocytes, significant 
differences in closure were seen at the 
72 hr. (p=.037) and 96 hr. (p=0.006) 
time points.
Cell viability was similar at 96 
hours post scratch in the normal 
and HS keratinocytes (Figure  2A). 
H o w e v e r,  c e l l  v i a b i l i t y  w a s 
significantly lower in chronic wound 
keratinocytes at 96 hours (p=0.0138) 
(Figure 2b). 
Increased apoptosis and necrosis 
was observed in CW compared to 
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FIGURE 2A: Differences in cell viability and cytokine production among 
Normal, HS and CW keratinocytes. Fluorescent microscopy showing live 
(blue) / dead (green) keratinocytes from three representative human 
samples, which were normal, having chronic wound and hidradenitis 
patient respectively. Staining was done 96 hours after a scratch was 
done on a confluent culture surface. Magnification=100X.  
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FIGURE 2B: Graph showing % viable cells (keratinocytes) in Normal 
(N), Hidradenitis (HS) and Chronic wound (CW) samples, 96 hours 
after scratch. There was a significant decrease in viability among CW 
compared to Normal and HS. 
normal and HS keratinocytes 96 
hours post-scratch (Figure 2C). Flow 
cytometry for Annexin V/PI demon-
strated that CW keratinocytes had a 
significantly higher rate of apoptosis 
(annexinV positive) and necrosis 
(annexinV-PI double positive cells) 
than normal (p=0.0075) and HS 
(p=0.028) keratinocytes.
Evaluation of cytokine concen-
tration from scratch assay culture 
supernatant showed significantly 
higher IL-1α and VEGF in normal 
keratinocytes compared to CW. In 
contrast, IL-22 levels were signifi-
cantly lower in the HS culture super-
natant (Figure 2d) than both CW and 
normal keratinocytes (p=0.0008). 
This finding indicates that IL-22 
and its downstream pathways merit 
further investigation as molecules of 
interest in HS pathogenesis.
Using a keratinocyte scratch 
assay, we were able to show that 
keratinocytes harvested from HS, 
CW, and normal skin exhibit distinct 
behaviors in response to in vitro 
wounding. Results indicate that cell 
viability, key cytokines, and growth 
factors may contribute to these 
observed differences in keratinocyte 
function. Inherent biologic mecha-
nisms at the level of the keratinocyte 
may contribute to delayed healing in 
chronic wounds and the pathogenesis 
of hidradenitis suppurativa.
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FIGURE 2C: AnnexinV/ PI double negative cells were highest in normal 
followed by HS group and lowest in CW across all samples.
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FIGURE 2D: HS keratinocytes had significantly lower production of IL-22 
in culture supernatant at all time points whereas, normal keratinocytes 
had a significant steady increase of VEGF and IL1-α over time compared 
to other groups.
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(FLOWleak[t]), where FLOWleak[t] 
is decreased by increasing Pao[t]. 
Data were plotted for one full cap-
nogram (Figure 2). At any t, if Pao[t] 
+ proximal sampling tube P (side-
stream sampling suction) was greater 
than zero (reverse FLOWleak), then 
FLOWleak[t] was set to zero in the 
Equation. 
INTRODUCTION
A leak in the sidestream sampling tube 
generates a characteristic capnogram 
(Figure 1A), where PCO2 on the 
first plateau is decreased because of 
dilution with room air (containing 
no CO2) into the sampling tube. 
Then, during the beginning of the 
next inspiration (last portion of the 
capnogram plateau), the increased 
a ir way open ing pressure ( Pao) 
decreases the leak to increase end-
tidal PCO2 (PetCO2) and raise the 
second plateau. In one patient, we 
observed the capnogram depicted 
in Figure 1B, where the waveform 
is rather narrow and of significant 
decreased amplitude ( PetCO2), 
which also turned out to be caused by 
a sidestream sampling tube leak. We 
hypothesized that the characteristic 
d u a l - pl ateau ca pnog r a m w it h 
sampling tube leak is not visible with 
a severe leak because the significant 
inf low of room air (containing no 
CO2) dilutes and decreases the first 
PCO2 plateau to near zero. Only 
the second PCO2 plateau is visible, 
when increasing Pao at the beginning 
of inspiration (last 
p o r t i o n  o f  t h e 
capnogram plateau) 
decreases the leak 
of room air into the 
sampling tube.
METHODS
To test this hypothesis, we developed 
a nu mer ica l a na lysis model to 
simulate mild and severe leaks in 
the sidestream sampling tube, using 
digital data from a patient capnogram 
(PCO2[t]) and Pao[t]) (Figure 2), 
where t is time and PCO2[t] is 
temporally advanced to account 
for transit t down the sampling 
tube. Equations were developed 
to calculate the f low through the 
sampling tube (FLOWst[t]) and the 
leak f low into the sampling tube 
FIGURE 1: A) Capnogram Displaying Mild Leak in Side-Stream Sampling 
Tube. B) Capnogram Displaying Severe Leak in Side-Stream Sampling 
Tube. 
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Unusual Clinical Capnogram Due to Sidetream 
Sampling Leak: Mechanism by Numerical Analysis
EQUATION
THEN, AT EACH T,   
MEASURED PCO2[T] =  FLOWST[T] X ACTUAL PCO2[T] / 
FLOWST[T] + FLOWLEAK[T] ) 
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RESULTS
Sampling tube resistance (R = P / 
FLOW) was 0.15 mmHg/(ml/min) 
(proximal sampling tube P of -30 
mmHg / sampling FLOW rate of 200 
ml/min). For the mild sampling tube 
leak condition, we used Rleak of 0.06 
mmHg/(ml/min), generating the 
dual-plateau capnogram depicted in 
Figure 2. For the severe capnometer 
sampling leak condition, we used 
Rleak of 0.007 mmHg/(ml/min), 
generating the narrow, low amplitude 
capnogram also displayed in Figure 2.
DISCUSSION
That the numerical analysis model 
(Figure 2) qualitatively generated 
the dual-plateau capnogram during 
mild sampling tube leak (Figure 
1A) and the narrow, low amplitude 
capnogram during severe sampling 
tube leak (Figure 1B) supports our 
proposed mechanisms underlying the 
PCO2[t] waveforms when air leaks 
into the sampling tube. For the severe 
sampling tube leak, the narrow, low 
amplitude capnogram is similar to 
the second plateau of the dual-plateau 
capnogram observed with a mild 
sampling tube leak. It is important to 
 Continued from p. 43
recognize Figure 1B as a severe leak 
into the capnometer sampling tube. 
Otherwise, the resulting narrow, 
low amplitude capnogram could be 
confused with low cardiac output 
(decreased CO2 deliver y to the 
lung), depression of tissue metabolic 
activity (decreased CO2 production), 
or excessive alveolar ventilation.
FIGURE 2: Numerical Analysis Model Calculated Graph Displaying Mild 
and Severe Leaks in Sidestream Sampling Tube with Expected PCO2 and 
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Glaucoma is a leading cause of irre-
versible blindness worldwide and is 
characterized by progressive destruc-
tion of neuronal connections between 
retinal ganglion cells (RGCs) and sub-
sequent visual systems in the brain. 
However, emerging evidence suggests 
that adult RGCs may be coaxed to 
behave in a manner similar to that 
investigation is the functional mecha-
nisms of lipid messengers, termed 
endocannabinoids (eCGs). These 
molecules modulate several types of 
developmental axon growth mecha-
nisms by activating cannabinoid 
receptor type 1 (CB1R) and G-protein 
coupled receptor 55 (GPR55).4 These 
receptors, a long with other key 
enzymatic players, are localized to 
corticofugal growth cones at axon ter-
minals. Activation of these receptors 
by eCBs, such as 2-arachidonoyl glyc-
erol, promotes normal fasciculation 
and may be sufficient for stimulating 
directional growth. Functionally 
significant components of this system 
are expressed in RGCs during embry-
onic development.5 However, the 
actions of eCGs on RGCs remain 
unclear. Elucidating 
these mechanisms 
will not only help to 
advance the under-
standing of neu-
ronal development, 
but also advance the 
understanding of 
how meaningful connections are 
formed in order to restore neural 
function in diseases such as glaucoma.
In this study, retinal explants 
were obtained from embryonic mice 
from day 15 and cultured onto poly-
D-lysine and laminin-coated glass 
coverslips in RGC growth medium. 
Cultures were maintained for 16 hours 
in the presence or absence of a drug, 
AM251, and then fixed with parafor-
maldehyde. AM251 is a high-affinity 
inverse agonist for the CB1R, which 
we believe promotes directional 
axon growth. Fixed retinal explants 
were then stained using immuno-
cytochemistry with a cocktail of 
fluorescent antibodies to label various 
aspects of the RGC, including actin 
filaments and microtubules, to assess 
growth cone and axonal development. 
Explants were then analyzed using 
multicolor confocal laser microscopy. 
Collected images were analyzed 
for quantity and quality of axonal 
growth.
Stimulation by AM251 signifi-
cantly increased mouse embryonic 
RGC axon growth overall (Figure 1). 
The total number of axon tips were 
significantly greater for AM251-
stimulated RGCs compared to those 
treated with vehicle alone (110 vs 70 
respectively, p=0.0151). Moreover, 
median axon length increased to 330 
um vs. 240 um for AM251 stimula-
tion vs. vehicle alone, respectively 
(p<0.00005). Within axon popula-
tions, AM251-stimulated RGCs also 
demonstrated a significantly greater 
proportion of axons with lengths 
extending beyond 300 um compared 
to null controls (0.405 vs. 0.305 
respectively, p<0.0005).
These results, then, not only con-
firm the current understanding that 
embryonic systems likely share fun-
damental mechanisms of neuritogen-
esis, but that modulation of growth 
cone CB1Rs by agents such as AM251 
may be effective in promoting axonal 
development in both the embry-
onic and adult CNS. Future studies 
evaluating the effects of AM251, or 
other eCGs, on adult RGCs could 
confirm these findings and provide 
further insights toward the potential 
for rescuing damaged neurons. This 
experiment represents a key step in 
the process of discovering the cure 
The current priority for investigation is the 
functional mechanisms of lipid messengers, 
termed endocannabinoids (eCGs).
observed during embryonic develop-
ment, when neural connections are 
normally formed. Although some 
mechanisms that govern successful 
regeneration of damaged neural con-
nections in the adult central nervous 
system may be unique, there must 
be significant overlap with certain 
fundamental aspects of embryonic 
neuritogenesis, polarization, and 
axon growth.1,2,3 Understanding the 
molecular mechanisms that govern 
the growth of connections between 
RGCs and the developing brain may 
ultimately lead to novel regenerative 
therapies for patients with glaucoma.
T h e  c u r r e n t  p r i o r i t y  f o r  Continued on p. 46
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for neurodegenerative diseases such 
as glaucoma.
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FIGURE 1: Influence of AM251 on 
Axonal Growth in a Murine Retinal 
Explant. AM251 increased the average 
number of axon tips compared to 
vehicle alone (110 vs 70, p = 0.0151).  
Stimulation by AM251 also induced 
growth of significantly longer axons 
(330 um) vs. DMSO vehicle (240 um, p 
< 0.00005). The number of total axons 
greater than 300 um was greater in 
the AM251 stimulated group (0.405) 
vs. DMSO treatment (0.305, p < 
0.0005).  There were no significant 
differences in retinal explant body size 
between the two treatment groups.
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Immune-compromised patients, 
including those with primary immune 
deficiencies and recipients of stem 
cell transplants, are at risk for persis-
tent Human Papillomavirus (HPV) 
infections and HPV-associated malig-
nancies. Chronic HPV infection is 
characterized by a weak CD4+ T-cell 
response and can lead to the develop-
ment of HPV-associated malignan-
cies.1 Recent vaccine studies suggest 
that cytotoxic T-cell responses against 
HPV antigens correlate with virus 
control.2 Adoptive transfer of third 
HPV-specific T-cells may be effica-
cious for immune deficient patients 
with HPV-associated diseases. 
HPV-derived E6 and E7 are attrac-
tive targets for T-cells as they are 
immunogenic and play critical roles 
in malignant transformation. The 
early oncoproteins HPV16 E6 and E7 
are ideal targets for the development 
of immunotherapy because they are 
only expressed in infected cells and 
malignant tumors, and they promote 
SFC/1-2x105 cells, [range 0-23.5] for 
irrelevant antigen) and evaluated lines 
were comprised of 26±0.02% CD8+ 
and 59±0.08% CD4+ T-cells. Current 
efforts are focused on developing a 
third-party T-cell bank and demon-
strating functional activity against 
HPV-expressing targets. Creating  a 
third-party bank would allow us to 
treat multiple patients using a single 
manufactured line, thereby reducing 
the time to treatment, and provide 
this form of therapy as option to all 
patients irrespective of donor source.5
In summary, expansion of HPV-
specific T-cells is feasible from vac-
cinated and unvaccinated healthy 
donors, and may be used as an “off-
the-shelf” immunotherapy for HPV-
associated diseases post-HSCT. 
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malignant transformation through 
the inactivation of the tumor sup-
pressor proteins p53 and pRb.3 A 
synthetic long peptide (SLP) vaccine 
against HPV16 E6 and E7 has induced 
regressions of vulvar intraepithelial 
neoplasia but is less effective against 
established cancers, suggesting that 
the endogenous immune system fails 
to eradicate bulky HPV-associated 
cancers even after effective immuno-
therapies.2 Recent efforts by Ramos 
et al. have demonstrated success in 
expanding HPV16 E6 and E7 specific 
cytotoxic T-lymphocytes (CTLs) 
from patients with HPV-associated 
cervical and oropharyngeal cancers.4 
We hypothesized that strategies for 
ex-vivo priming and expansion of 
antigen-inexperienced and anergic 
T-cells would enable generation of 
HPV-specific T-cells irrespective of 
donor source; these cells can then 
serve as components of an off-the-
shelf third-party bank of therapeutic 
T-cells.
We evaluated the feasibility of 
generating HPV-specific T-cells from 
peripheral blood of HPV-primed (n=2) 
and non-primed healthy donors (n=12) 
using GMP-compliant methodolo-
gies. Antigen presenting cells pulsed 
with HPV antigens were used to 
stimulate T-cells in combination with 
different cytokines.
Preliminary results show we gener-
ated T-cells targeting HPV antigens 
from 8/14 donors. T-cells expanded 
with a 142 median fold expansion 
after 23-25 days. The resultant product 
specifically recognized E6 or E7 pro-
teins by IFN-y ELISpot (mean 109.7 
SFC/1-2x105 cells [range 12.5-334] 
against HPV compared to mean 6.1 
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FIGURE: Descriptions of DTI Imaging Metrics (A,B) Images show smaller 
hypoxic corpus callosum FA values (decreased signal intensity) and 
volume (C).
Mortality and morbidity in the 
severe/complex congenital heart dis-
ease (CHD) population have been sig-
nificantly reduced due to advances in 
neonatal cardiac surgery and hospital 
care. Despite these successes, CHD 
patients are at risk for developing 
long-term neurological deficits. Non-
invasive peri-operative neuroimaging 
has suggested white matter (WM) 
underdevelopment and/or injury as 
a possible etiology.1,2,3 Despite these 
findings, the developmental mecha-
nisms underpinning WM deficits in 
CHD remain largely unexplored due 
to the technical challenges of in utero 
brain imaging and ethical concerns 
regarding the use of invasive tech-
nologies. To address these shortcom-
ings, a porcine hypoxia model has 
been developed to recapitulate the 
WM pathologies associated with pre-
operative cerebral hypoxia in CHD. 
In this preliminary study, diffusion 
tensor imaging (DTI) was used to 
assess the extent of WM macroscopic 
and microstructural dysmaturation 
due to hypoxia in the porcine model.
DTI is an MRI imaging modality 
that can provide information about 
the microstructure of brain tissue by 
measuring water diffusion. At each 
voxel in an image, water diffusion is 
represented in three dimensions by 
ellipses that show the principle and 
radial directions of water movement. 
Fractional anisotropy (FA) is a calcu-
lated value that indirectly measures 
organization of WM by assessing the 
radial restriction of water diffusion 
by tissue microstructure (Figure A). 
Low FA values in WM regions have 
been correlated with reduced struc-
tural integrity and hypomyelination 
in a variety of neurological diseases. 
Axial diffusivity (AD) is the prin-
ciple water diffusion coefficient for 
a given diffusion ellipse (Figure B). 
Decreases in AD have been associ-
ated with axonal injury.4
Female Yorkshire piglets were 
housed in a hypoxic environment 
(10.5% FiO2) between days 3 and 14 
after birth in order to model brain 
development under hypoxic condi-
tions during the late third gestational 
trimester and early infancy (normoxic 
control n=2, experimental n=3). At 
14 days of age, DTI images were 
obtained from postmortem brains 
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using a segmented diffusion echo 
planar MRI sequence (Figure C). 
Brain volume, FA, and AD were com-
puted for the corpus callosum and the 
internal capsule (Table). 
Following hypoxia, corpus cal-
losum and internal capsule vol-
umes were 14 percent and 22 percent 
smaller, respectively, despite a mod-
erate total brain volume difference 
of 4 percent. In addition, hypoxic 
corpus callosum FA values were on 
average 13 percent lower than nor-
moxic controls, whereas FA values 
for the internal capsule were only 
2 percent lower. Hypoxic corpus 
callosum and internal capsule AD 
values were 9 percent and 12 percent 
lower, respectively, compared with 
normoxic controls. 
These preliminary findings pro-
vide evidence that cerebral hypoxia 
results in reduced WM matura-
tion during critical periods of brain 
development. The reduction in WM 
volume induced by hypoxia is likely 
indicative of less myelin content 
and/or axons. Lower FA values in the 
corpus callosum and internal capsule 
after hypoxia suggest disorganization 
and hypomyelination of these WM 
structures. Furthermore, hypoxic 
AD values were lower for both the 
corpus callosum and internal capsule 
indicating potential axonal injury.
Dysmaturation of the corpus 
callosum and internal capsule can 
diminish neural connections trans-
mitting important motor, sensory, 
and cognitive information. Studies of 
CHD patients have shown deficien-
cies in the aforementioned neural 
functions.1,2,3 The findings presented 
here strengthen the evidence sup-
porting pre-operative hypoxia as an 
etiology for the long-term neurologic 
sequelae of CHD. Future studies 
involving the hypoxic pre-operative 
porcine model of CHD will aim to 
correlate DTI findings with WM 
histological changes.
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TABLE: Comparison of Normoxic (Nx) and Hypoxic (Hx) Cerebral 
Structure Volume, FA, and AD ± Standard Deviation
Volume 
(mm3)
Average FA Average AD 
(10-3 mm2/s)
Total Brain Nx 47,040 ± 1,680 — —
Hx 45,030 ± 3,820 — —
Corpus callosum Nx 228 ± 2 0.39 ± 0.03 0.22 ± 0.02
Hx 195 ± 17 0.34 ± 0.02 0.20 ± 0.03
Internal capsule Nx 234 ± 28 0.59 ± 0.01 0.33 ± 0.01
Hx 183 ± 41 0.58 ± 0.05 0.29 ± 0.03
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FIGURE 1: PKA Stimulation Increases Gpr83 mRNA Expression.
Immortalized human renal proximal tubule cells were incubated with 
forskolin (10 µM, 30 min) in the presence or absence of the PKA inhibitor 
H-89 (20 µM, 1 h). Forskolin activates adenylyl cyclase and increases 
intracellular levels of cAMP, which in turn activates protein kinase A. After 
incubation, the human renal proximal tubule cells were collected, lysed, 
and RNA extracted. mRNA expression was quantified by qRT-PCR. N=4/
group; P<0.05 vs all others, one-way ANOVA, Holm-Sidak test.
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The G protein-coupled receptor 
(GPCR) 83 (Gpr83) is an orphan 
receptor belonging to the rhodopsin-
like family of GPCRs.1 Gpr83 was 
originally identif ied as a gluco-
corticoid-induced transcript in a 
murine T-cell line and referred to 
as glucocorticoid-induced receptor.2 
Gpr83 is expressed in brain hypo-
thalamic nuclei relevant to energy 
metabolism control and has a role 
in the central regulation of energy 
metabolism.3 Gpr83 is also expressed 
in the kidney, but its function is 
unknown. We found that Gpr83 is 
expressed in mouse renal proximal 
and distal convoluted tubules, as 
well as in human renal proximal 
tubule cells (hRPTCs). High salt 
diet increased Gpr83 transcription 
by 2-fold (P<0.05; n=4/group) in Swiss 
Jim Lambert (SJL/J) and Bagg Albino 
(BALB/c) salt-resistant mice, relative 
to C57 Black (C57Bl/6J) salt-sensitive 
mice. In C57Bl/6J mice on normal salt 
diet, the lack of 
one (Gpr83+/-) 
or both Gpr83 
(Gpr83-/-) alleles 
resulted in an 
increase in sys-
tolic blood pres-
sure (SBP, ~20 
mm Hg (P<0.05; 
n=4/group, mea-
sured under anesthesia) compared 
with Gpr83+/+ littermates, suggesting 
that Gpr83 is needed to keep a normal 
BP. Renal-specific Gpr83 silencing 
by the renal subcapsular infusion 
of Gpr83 siRNA (3 µg/day; 7 days) 
increased SBP in C57Bl/6J mice on 
a normal salt diet, relative to mice 
treated with non-silencing siRNA 
(120±5 vs 98±6 mmHg; P<0.05; n=4/
group). In hRPTCs, forskolin (10 
µM, 30 min) increased Gpr83 mRNA 
(3.5±0.06 vs 1.0±0.12-fold; P<0.05; 
n=4-5/group), the effect of which 
was blocked by the protein kinase 
A (PKA) inhibitor H-89 (20 µM, 1 
h). In hRPTCs, phorbol myristate 
acetate (200 ng/mL, 30 min), which 
activates protein kinase C (PKC), 
decreased Gpr83 mRNA (0.43±0.2 vs 
1.0±0.04-fold, P<0.05; n=4-5/group), 
an effect that was partially blocked 
by the PKC inhibitor GF109203x 
(1µM, 1h). Stimulation of hRPTCs 
with ZnCl2 (100 µM, 1 h), an acti-
vator of Gpr834, increased AKT 
(2.5±0.5 vs 1.0±0.06-fold; P<0.05; 
n=4-5/group) and ERK1/2 (1.4±0.1 vs 
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GPR83 Function Contributes to Salt Resistance
Gpr83 function may be mediated by the phosphoryla-
tion of AKT/ERK1/2 and dephosphorylation of MAPK. 
Thus, several pathways are involved in the Gpr83-
mediated regulation of salt-sensitive hypertension.
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1.0±0.08-fold; P<0.05; n=4-5/group) 
phosphorylation and decreased p-38 
mitogen-activated protein kinase 
(MAPK) phosphorylation (0.1±0.05 
vs 1.0±0.1-fold; P<0.05; n=4-5/group). 
Our results suggest that Gpr83 may 
protect against the development of 
salt sensitivity. PKA positively while 
PKC negatively regulates Gpr83 
expression. Gpr83 function may be 
mediated by the phosphorylation 
of AKT/ERK1/2 and dephosphory-
lation of MAPK. Thus, several 
pathways are involved in the Gpr83-
mediated regulation of salt-sensitive 
hypertension.
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FIGURE 2: Gpr83 Activation Decreases the Phosphorylation of p38 
MAPK
Immortalized human renal proximal tubule cells were incubated with 
vehicle or ZnCl2 (100 µM, 1 h), which stimulates Gpr83 activity. The 
cells were treated with non-silencing siRNA or Gpr83-siRNA (30nM, 
72 h). After incubation, the cells were collected, lysed, and proteins 
were extracted. Protein expression of phosphorylated p38 MAPK was 
quantified by western blot. N=4/group; P<0.05 vs all others; #P<0.05 vs 
cells treated with non-silencing siRNA, one-way ANOVA, Holm-Sidak test.
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Chronic wounds are classified as 
wounds that have failed to heal after 
three months of appropriate wound 
care. They affect approximately 6.5 
million Americans, with a prevalence 
of 1 percent and costs estimated at 
$25 billion per year. However, studies 
have shown that medical students 
receive limited wound care training 
during their medical school career.
The purpose of this study was 
to investigate medical students’ 
exposure to chronic wound care 
education through didactic experi-
ence and clinical exposure at a single 
medical school to further assess stu-
dents’ confidence level with respect 
to chronic wound management in a 
single medical school.
A survey of 11 questions testing 
the fundamentals of chronic wound 
management was developed with 
the assistance of a trained wound 
care nurse practitioner based on the 
Agency for Healthcare Research 
and Quality (AHRQ) guidelines 
on chronic wounds (Table). The 
questionnaire was administered 
using the Internet-based REDCap 
survey tool to first-, second-, third-, 
and fourth-year medical students at 
TABLE: Seven questions from a survey based on current evidence-
based AHRQ guidelines assessing the fundamentals of chronic wound 
management (correct answers in blue).
the George Washington University 
School of Medicine and Health 
Sciences through the class listervs. 
For the purposes of analysis, students 
were organized into two groups: 
pre-clinical (years one and two), and 
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Question Answer Options
1.  At what time is a wound/ulcer considered 
chronic?
❍  2 weeks 
❍  4 weeks 
❍  8 weeks 
●  12 weeks
2.  The determination of the Ankle Brachial Index 
(ABI) is crucial in the assessment of a chronic 
non-healing led ulcer. To initially assess arterial 
circulation for a chronic non-healing leg or foot 
ulcer, a patient should have:
❍  Arteriogram 
●  Pedal pulses palpated 
❍  Hand-held Doppler Exam 
❍  Non-invasive arterial studies 
❍  Ankle Brachial Index measurement
3.  What percentage of healing per week 
represents normal healing?
❍  0–5% 
❍  5–10% 
●  10–15% 
❍  15–20% 
❍  20–25%
4.  How frequently should patients with diabetes 
undergo diabetic foot exams?
❍  Every week 
❍  Every month 
❍  Every 6 months 
●  Every year 
❍  Every 2 years
5.  Clinicians should consider re-evaluation of 
the ulcer and initiating the use of advanced 
treatment options if the diabetic foot ulcer 
or venous leg ulcer has not healed by what 
percentage in four weeks?
❍  10% 
❍  20% 
❍  30% 
●  40% 
❍  50%
6.  What is considered the gold standard for 
offloading plantar diabetic foot ulcers?
❍  Postoperative shoe 
❍  Unna boot 
❍  Removable walking boot 
●  Total contact casting 
❍  Half show
7.  The standard of care for ulcer management 
using dressing is:
❍  Saline wet-to-dry 
❍  Wound VAC 
❍  ACE bandage 
●  Hydrogel 
❍  Xeroform
Medical Education:
Medical Student Competency in 
Wound Care Guidelines
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clinical (years three and four). Data 
was analyzed using T-test, Fisher’s 
Exact and Chi Square performed 
using GraphPad Prism 5.0.
Of the 709 medical students who 
were surveyed, completed question-
naires were received from 60 stu-
dents, 29 pre-clinical and 31 clinical, 
with an estimated response rate of 
8.5%. Questionnaire performance 
on chronic wound care guidelines 
was suboptimal in both groups, 
preclinical and clinical. The clinical 
group correctly answered 34.02% of 
questions and pre-clinical 29.47% 
(p=0.1551). Medical students reported 
a mean of 1.38 ± 0.94 hours of didac-
tics on wound healing, tissue injury, 
or wound management (p=0.0006), 
with a significant difference between 
preclinical group (0.97 ± 0.94) and 
clinical group (1.77 ± 0.76)s.  Pre-
clinical and clinical groups had no 
significant differences in correct 
response rate on most of the survey 
questions (Table). However, for the 
question pertaining 
to recommended fre-
quenc y of d iabetic 
f o ot  e x a m i n a t ion , 
9.52% of preclinical 
students responded 
correctly compa red 
to 55.56% of clinical 
students (p=0.0019). 
Self-reported comfort 
level of medical students in man-
aging chronic wounds, which was 
measured on a scale of zero to 10, 
was not correlated with correct 
responses on this survey. However, 
we did note that individuals reporting 
higher subjective comfort scores 
had received more wound-related 
didactic teaching hours (2.38 ±0.74 
compared to 1.61±0.84, p=0.02). 
Despite prevalence and cost asso-
ciated with chronic wounds, there is 
an unmet need for guideline-based 
chronic wound management training 
for medical students. In order to 
address this deficiency, we recom-
mend re-evaluating the didactic 
wound care exposure to focus on 
improving knowledge and comfort 
level using guideline-based chronic 
wound management across the med-
ical school curriculum.
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Despite prevalence and cost associated with 
chronic wounds, there is an unmet need for 
guideline-based chronic wound management 
training for medical students. 
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In the coming years, there is expected 
to be significant increase in demand 
for rheumatologists; however, the 
number of trained rheumatologists 
is declining.1 Interest in rheuma-
tology often begins during medical 
school, and many rheumatologists 
report interactions with a mentor as a 
driving force behind their decision to 
select rheumatology as a career.2,3 The 
American College of Rheumatology 
has implemented strategies to try to 
increase medical student interest in 
rheumatology, including the Choose 
Rheumatology program. We sought 
to investigate the impact of a student-
led rheumatology interest group on 
student uptake of the rheumatology 
elective and submissions of abstracts 
and manuscripts.
In April 2015, medical students at 
the George Washington University 
(GW) School of Medicine and Health 
Sciences established a student-led 
Rheumatology Interest Group. At 
the inaugural meeting, the Choose 
Rheumatology team presented on 
rheumatology careers, faculty gave 
testimonials, and patients spoke about 
the impact of their rheumatologist 
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on their lives. Follow-up meetings 
included a meeting on identifying 
mentors and research projects and 
two joint injection workshops. 
Data was collected from the two 
years before initiation of the student 
interest group (2012-14) and the year 
following initiation of the group 
(2015-16) based on three parameters: 
rheumatology elective enrollment; 
medical student abstract submissions 
to GW Research Day; and manu-
scripts published. The mean number 
of student-rheumatology interactions 
per six months in the pre- and post-
intervention period were assessed for 
each parameter. Data was analyzed 
using GraphPad Prism 5.03. 
Student enrollment in the rheu-
matolog y elective signif icantly 
increased following the development 
of the Rheumatology Interest Group, 
with a mean number of students per 
six months of 2.0 ± 0.36 in the pre-
intervention period and 7.5 ± 3.5 in the 
post-intervention period (p=0.021) 
(Figure 1A).
The number of abstract submis-
sions also significantly increased 
with 0.5 ± 0.34 submissions in the 
pre-intervention period compared 
to 7.0 ± 4.0 in the post-intervention 
period (p=0.017) (Figure 1B).
The number of manuscripts sub-
mitted by student faculty dyads 
has increased since development of 
the Rheumatology Interest Group 
from 0.16 ± 0.16 to 1.5 ± 0.5 (p=0.013) 
(Figure 1C).
The Rheumatology Workforce 
FIGURE: A) Mean number of 
students per six months enrolled in 
rheumatology elective in the time 
periods prior to and subsequent to 
development of the rheumatology 
interest group. B) Mean number 
of abstracts submitted by student-
faculty dyads per six-months 
prior to and subsequent to the 
development of the rheumatology 
interest group. C) Mean number 
of manuscripts submitted by student-faculty dyads per six-months prior 
to and subsequent to the development of the rheumatology interest 
group. 
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Study has shown that the supply 
of rheumatologists entering prac-
tice is not expected to meet future 
demands.1 To avoid a critical shortage 
of rheumatologists, efforts must 
focus on increasing interest in rheu-
matology among future physicians. 
Exposure to a field in medical school 
impacts future career decisions, with 
45 percent of students stating that 
subspecialty exposure in medical 
school played a significant role in 
career choices and 27 percent citing a 
department or teacher as influencing 
career decisions.2 
This study demonstrated that a 
student-led Rheumatology Interest 
Group, supported by rheumatology 
faculty, can significantly increase 
medical student interest in rheu-
matology during medical school. 
Participation in the rheumatology 
elective, and abstract and manu-
script submissions all significantly 
increased after creation of the 
interest group. This simple, low-cost 
intervention would be easily repli-
cated at other institutions and could 
dramatically augment the student 
interest in rheumatology.
A simple and low-cost interven-
tion of development of a student-led 
interest group, coupled with a Choose 
Rheumatology campus visit, pro-
vided students with increased expo-
sure to rheumatology and increased 
access to mentors and research proj-
ects. These opportunities generated 
enthusiasm for the field as evidenced 
by greater enrollment in the rheuma-
tology clinical elective, and abstract 
and manuscript submissions. 
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Traditionally, anatomy is one of 
the first subjects taught in medical 
school. Practicing physicians have 
commented on medical students’ 
poor anatomical knowledge in surgi-
cally oriented clerkships. Literature 
also shows that correlating clinical 
and anatomical sciences throughout 
early medical education may improve 
anatomical knowledge retention. 
With major medical school curricular 
changes happening across the nation, 
more quantitative data confirming 
this correlation is needed. 
The medical curriculum at the 
George Washington Universit y 
School of Medicine and Health 
Sciences recently underwent reor-
ganization, transforming an earlier 
discipline-based curriculum to that 
of an integrated system-based one. In 
order to determine whether reorga-
nization has an effect on anatomical 
knowledge retention, comparisons 
of anatomical knowledge between 
classes in the different curricula were 
made. Students from the last class 
of the discipline-based curriculum 
(2013) and students from the first class 
of the new, integrated curriculum 
(2016) completed the same 27-ques-
tion test before beginning their 
general surgery and obstetrics and 
gynecology (OB/GYN) rotations. 
Scores for specific anatomy catego-
ries related to general surgery and 
OB/GYN were then analyzed and 
compared between classes. 
Comparing the scores from the 
2013 and 2016 cohorts, there was an 
overall decrease in retention from 
65.69% to 63.64% (Table). Item 
analysis per topic revealed a mean 
decrease in surgical anatomy and OB/
GYN anatomy retention of 2.53% and 
1.58%, respectively. There was a 21.6% 
increase in inguinal canal anatomy 
retention and a 17.33% increase in 
appendix-related questions. There 
was also a 12.02% decrease in fallopian 
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TABLE: Scores from 2013 vs. 2016: Retention Comparison
Complication by 
Broad Category
Number of 
test items
2013 Correct 
(%)
2016 Correct 
(%)
Change in 
Retention 
2013–16 (%)
Surgery
Inguinal canal 2 MCQs 45.28 66.87 21.5922
Vasculature 3 MCQs 30.74 35.74 5.0026
Abdomen 3 MCQs 47.63 48.19 0.5671
Appendix 4 MCQs 71.53 88.86 17.3297
MEAN TEST SCORE 13 MCQs 66.98 64.45 -2.53
OB/Gyn
Uterine 2 MCQs 45.69 55.73 10.0353
Vasculature 4 MCQs 49.14 64.31 15.1671
Peritoneal cavity 1 MCQ 82.76 92.17 9.4114
Fallopian tube 1 MCQ 63.22 51.20 -12.0184
Embryology 3 MCQs 47.92 48.79 0.877
Placenta 1 MCQ 80.14 78.92 -1.217
MEAN TEST SCORE 14 MCQ 64.40 62.82 - 1.58
Overall Retention for Both Disciplines 2013: 65.69 2016: 63.64 -2.05
tube anatomy retention. 
In conclusion, when comparing 
the 2013 to the 2016 data, there were 
overall decreases in retention for 
the anatomy as it relates to general 
surger y and OB/GYN; however, 
improvements were noted for specific 
topic areas. These results suggest that 
the change in retention is apparent 
and multifactorial. The differences 
between surgical anatomy retention 
and OB/GYN anatomy retention 
scores may be related to the way the 
subject matter was organized and pre-
sented or how the anatomic founda-
tional knowledge was integrated with 
its clinical relevance. Although inte-
grative learning has been associated 
with better retention, more studies 
will have to be conducted to validate 
this statement. Finally, analyzing the 
subject matter, curriculum structure, 
clinical focus, and objectives should 
be evaluated moving forward. 
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With the virtually ubiquitous usage 
of social media, business and medical 
professionals have become increas-
ingly aware of the presence of, and 
consequences related to, use of spcial 
media. The American Congress of 
Obstetricians and Gynecologists 
(ACOG) warns its members of the 
dangers of posting inappropriate 
information and pictures. They 
also produced a video titled “Social 
Media Professionalism in the Medical 
Community.” Studies show that 
physicians are being “friended” 
by their patients on social media 
sites.1 Employers are increasingly 
screening their applicants’ social 
media behavior for professionalism, 
and this is extending to the medical 
profession as well. As of 2009, 10 per-
cent of residency programs used social 
media to screen applicants.2 A 2012 
survey found most residency appli-
cants altered their social media profile 
before the residency match process.3
First and last name, medical 
school, and current photo were pro-
vided for each applicant interviewed 
for the OB/GYN residency position 
at Brown University. Each appli-
cant was searched on Facebook, 
Instagram, Twitter, LinkedIn, and 
Google. When there were multiple 
accounts with the same name, the 
medical school and photo were used 
to differentiate accounts. A quanti-
tative analysis was performed with 
a final calculation of the number of 
applicants with publically accessible 
profiles, private profiles, and any 
inappropriate content. Inappropriate 
content was defined as behaving inap-
propriately in the medical setting, 
violating patient privacy, boasting 
of substance use, sexually explicit 
content, or inappropriate (foul/racist/
sexist) language.4,5
The accounts of 87 residency 
applicants were searched for publi-
cally available information. None 
of the applicants met the criteria 
for inappropriate social network 
material. Twenty-two out of the 87 
applicants had Facebook content a 
“non-friend” could view. Twitter was 
not a popular interface, with only 
seven accounts easily searchable, and 
among those accounts, some lim-
ited content to approved followers. 
Instagram had the greatest number 
of private accounts with only four 
accounts with pictures available to 
the public. No LinkedIn or Google 
searches included inappropriate 
content. During a post-Match Day 
search in July 2016, results were 
not significantly different from the 
original search. 
There were no instances of inap-
propriate content among the candi-
dates’ publically available social media 
postings. One of the difficulties of the 
search process was that applicants 
with common names often could 
not be differentiated, even utilizing 
their picture and medical school. 
This suggests that medical students’ 
public persona is professional either 
because it reflects their behavior, or 
they are finding ways to keep their 
private lives disconnected from their 
professional career. This was some-
times accomplished by using a maiden 
name, nick-name, or middle name as 
an account username, which is most 
easily accomplished on Twitter and 
Instagram due to the requirement of 
picking a username. Medical students 
also did not significantly change their 
privacy settings immediately fol-
lowing Match Day. Whether students 
are professional in all aspects of their 
social media or are merely modifying 
what is publically available, it was 
striking that no instance of unpro-
fessional content was visible. This 
may reflect an increased awareness 
of social norms through outlets such 
as ACOG or counseling from men-
tors. Whether this will translate into 
decreased episodes of unprofession-
alism during residency and practice 
remains to be seen.
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